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Abstract  
Our group recently observed that male mice containing a deletion for the gene encoding 
the thiol oxidoreductase glutaredoxin-2 (GRX2) were protected from diet-induced obesity (DIO) 
and the development of related disorders (e.g. fatty liver disease). This effect was associated with 
increased fuel combustion in muscles. In the present study, I assessed if deleting the Grx2 gene 
protected female mice from DIO. Unlike male mice, in this study female wild-type (WT) 
littermates were completely resistant to developing DIO and related co-morbidities. Additionally, 
deletion of the Grx2 gene did not alter the weight gain profiles, adiposity, intrahepatic fatty acid 
and glycogen levels, or circulating triglycerides in these mice. Furthermore, while differences in 
reactive oxygen species generation in liver mitochondria were observed, this trend was not 
present in muscle mitochondria. Mitochondrial bioenergetics data revealed no differences in 
mitochondrial respiration between WT and GRX2-deficient female mice fed a control or high-fat 
diet.  
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1.1 Energy Metabolism 
The “universal energy currency” for cells is commonly known to be adenosine triphosphate 
(ATP) as it drives almost all physiological processes ranging from the movement of muscles for 
locomotion to aiding in the transport of molecules into cells via active transport (1). Often 
mitochondria are referred to as the “powerhouse” for good reason since these double-membraned 
organelles are responsible for producing ~90% of the ATP in many mammalian cells (1). The 
superior ATP producing capacity of mitochondria is attributed to its highly-folded and 
selectively permeable mitochondrial inner membrane (MIM), which allows the conservation of a 
large amount of energy liberated during fuel metabolism for the production of ATP (2). 
Additionally, the highly folding nature of the MIM creates deep invaginations called cristae. 
These cristae are enriched in various enzymes and multi-subunit complexes that are critical for 
fuel metabolism and ATP production (1). Furthermore, while mammalian mitochondrial DNA 
(mtDNA) only consists of 15,000-17,000 base pairs (bp) of double stranded DNA, this DNA has 
been highly conserved with estimations of sequence evolution at 2% per million years (3). This 
small amount of mtDNA transcribes only 13 protein products that are all involved in the electron 
transport chain (ETC) and crucial for mitochondrial function (3).  
The metabolism of carbon sources, such as glucose, fatty acids, and amino acids, for energy 
is essential for all mammalian life. Fuel combustion and cellular respiration occurs in 
mitochondria, subsequently generating a proton-motive force (PMF). This PMF is composed of 
two components, an electrical (Dym) and chemical (DpH) gradient, making up the 
electrochemical gradient. The electrochemical gradient occurs across the MIM with the chemical 
gradient making up the majority of stored potential energy (4). A description of carbon 
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oxidation, along with how mitochondria harness potential energy to form ATP, will be conveyed 
in the following sections.  
1.1.1 Glycolysis  
The complete oxidation of glucose to carbon dioxide and water results in the release of 
2,840 kJ/mol energy (2). Heterotrophs such as herbivores and omnivores meet most of their 
glucose demands through the consumption of autotrophs (e.g. plants), which utilize solar energy 
in conjunction with CO2 and H2O to form sugars. Carnivores, on the other hand, rely mostly on 
gluconeogenesis in hepatic tissue to meet their glucose demands, a process that can form glucose 
from non-carbohydrate molecules such as amino acids and glycerol (2). Use of glucose for the 
production of ATP depends on its uptake, transformation, and degradation in the cytosol of 
mammalian cells. Full degradation of glucose by glycolysis yields two pyruvate, which can 
undergo further oxidation in mitochondria when molecular oxygen is available (aerobic 
respiration) (2). During low O2, however, pyruvate is reduced in the presence of NADH by 
lactate dehydrogenase, forming lactate (2). This is called anaerobic respiration and is vital for 
maintaining glycolytic flux when O2 is limiting (2). Glycolysis produces a net yield of 2 ATP per 
glucose molecule, along with reducing 2 cytosolic NAD+ (Equation 1.1) (2). Glycolysis utilizes 
10 enzymes to generate ATP and pyruvate, which can be divided into two sub-categories (Figure 
1.1): the preparatory phase (requires ATP input), and the payoff  phase (yields ATP) (2).  
Glycolysis takes place in the cytoplasm of mammalian cells, but glucose has to be 
transported first from the intestinal tract, into the blood stream, and then across the cell 
membrane. This transport begins in the gut lumen where glucose and galactose are taken up by 
epithelial cells by glucose transporter-2 (GLUT2) or the symporter, sodium-glucose transporter 
(SGLT) (2). It is important to recognize that fructose can be taken up into epithelial cells by the 
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fructose transporter, GLUT5 (2). Once in the epithelial cell, glucose/galactose/fructose can be 
transported across the basolateral side of the cell by GLUT2, entering the blood stream (2). 
These molecules then enter the hepatic portal vein with galactose/fructose taken up by the liver 
and metabolized, while most of the glucose remains in circulation to be taken up by other cells 
such as myocytes. This uptake of glucose is typically insulin dependent; insulin signalling 
induces translocation of GLUT4 transporters to the cell membrane allowing glucose uptake (2). 
It is in this manner that organisms maintain blood glucose homeostasis. Once in the cell, the first 
step of glucose metabolism is catalysis by hexokinase, which expends ATP to phosphorylate 
glucose generating glucose-6-phosphate (2). Hexokinase has four isozymes (I to IV) with 
hexokinase IV differing in kinetic and regulatory properties and often referred to as glucokinase 
(2). One of the key differences between hexokinase I-III and IV is their affinity for glucose and 
regulation by glucose-6-phosphate (2). Hexokinase IV has a lower affinity for glucose, with a 
Km of 5 mM in rats (compared to 0.007-0.045 mM for hexokinase I-III), and is not allosterically 
inhibited by glucose-6-phosphate (2,5). These characteristics allow the liver to take in large 
amounts of glucose after a meal for storage. However, when glucose is scarce, it allows for 
glucose, generated by gluconeogenesis, to leave the cell and be transported to cells such as 
myocytes (2). Next, the hexose ring of glucose-6-phosphate is rearranged by phosphohexose 
isomerase, generating fructose-6-phosphate (2). Once formed, fructose-6-phosphate is 
phosphorylated on the C-1 position by phosphofructokinase-1 in an ATP dependent fashion, 
yielding fructose-1,6-bisphosphate (2). The next step results in the cleavage of fructose-1,6-
bisphosphate into two 3-carbon sugar molecules: glyceraldehyde-3-phosphate and 
dihydroxyacetone phosphate (2). This step is catalyzed by aldolase and the resulting 
dihydroxyacetone phosphate is transformed into another glyceraldehyde-3-phosphate molecule  
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Figure 1.1: Glycolysis.  
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by triose phosphate isomerase (2). Once formed, the two glyceraldehyde-3-phosphate molecules 
generated by the preparatory phase are used in the payoff phase.  
The payoff phase starts with the phosphorylation of glyceraldehyde-3-phosphate by 
glyceraldehyde-3-phosphate dehydrogenase (2). Phosphorylation requires inorganic phosphate 
and is coupled to glyceraldehyde-3-phosphate oxidation, generating 1,3-bisphosphoglycerate and 
NADH (2). It is important to note that all the steps of the payoff phase occur in duplicate, as one 
glucose produces 2 glyceraldehyde-3-phosphate molecules. Next, the high energy 1,3-
bisphosphoglycerate is utilized to drive the substrate level phosphorylation of ADP, producing 
ATP and 3-phosphoglycerate, which is catalyzed by phosphoglycerate kinase (2). Following this, 
phosphoglycerate mutase moves the phosphate from the C-3 position to C-2, producing 2-
phosphoglycerate (2). This is achieved through a dehydration reaction which forms a double 
bond between the C-1 and C-2 positions (2). Finally, phosphoenolpyruvate is then used for the 
substrate level phosphorylation of ADP, producing ATP, a reaction that is mediated by pyruvate 
kinase (2). The ATP produced from glycolysis is utilized to do work while the NADH must be 
shuttled into the mitochondrial matrix to donate its electrons to the ETC.  
The MIM is impermeable to NADH; therefore, there are two mechanisms by which this 
electron carrier donates its electrons to the ETC: 1) the malate-aspartate shuttle and 2) the 
glycerol-3-phosphate shuttle. The malate-aspartate shuttle works by malate dehydrogenase 
utilizing NADH to yield malate from oxaloacetate which can be transported across the MIM by 
the malate-a-ketoglutarate transporter (2). Matrix malate dehydrogenase can then regenerate 
NADH and oxaloacetate allowing NADH to donate its electrons to complex I (2). Oxaloacetate 
must then be returned to the cytosol in order to allow the cycle to continue and this is achieved 
through its conversion to aspartate and shuttling through the glutamate-aspartate transporter (2). 
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Alternatively, the glycerol-3-phosphate shuttle utilizes cytosolic glycerol-3-phosphate 
dehydrogenase and NADH to convert dihydroxyacetone into glycerol-3-phosphate (2). An 
isozyme of glycerol-3-phosphate dehydrogenase, which is bound to the outer face of the MIM, 
reoxidizes the glycerol-3-phosphate back into dihydroxyacetone. The FAD subunit of the MIM 
bound glycerol-3-phosphate dehydrogenase accepts the electrons during this reaction and 
donates them to the Q pool (2). Since the electrons from the glycerol-3-phosphate shuttle 
bypasses complex I, each NADH only produces ~1.5 instead of ~2.5 ATP (2).  
 
Equation 1.1: 
Glucose + 2 NAD+ + 2 ADP + 2 Pi à 2 Pyruvate + 2 NADH + 2 H+ + 2 ATP + 2 H2O 
 
1.1.2 Krebs Cycle 
The Krebs cycle (citric acid cycle or tricarboxylic acid cycle) is the most central 
metabolic pathway in all organisms as it is responsible for both the production of ATP and 
genesis of precursors for the biosynthesis of macromolecules. The cycle is comprised of eight 
enzymatic steps that couple the oxidation of various substrates to the production of the electron 
carriers NADH, FADH2, and GTP/ATP (Figure 1.2; Equation 1.3) (2). A number of different 
fuels, including amino acids, ketone bodies, fatty acids, and many others, can serve as substrates 
for the Krebs cycle (2). Oxidation of these fuels and the formation of the different electron 
carriers is coupled to the irreversible production of CO2. The full oxidation of glucose, when O2 
is available, first requires the production of acetyl-CoA from pyruvate after the import of 
pyruvate into the mitochondrial matrix. The transport of pyruvate into the mitochondrial matrix 
is facilitated by mitochondrial pyruvate carrier (MPC) transporters (6). Mitochondria contain two 
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MPC isoforms, MPC1 and 2, which couple the unfavourable transport of pyruvate to the return 
of protons into the matrix (6). 
Once inside the matrix of the mitochondria, the pyruvate must be converted into acetyl-
CoA by pyruvate dehydrogenase (Equation 1.2). The pyruvate dehydrogenase complex (PDH) is 
made up of three subunits: E1: pyruvate dehydrogenase, E2: dihydrolipoyl transacetylase, and 
E3: dihydrolipoyl dehydrogenase (2). The E1 subunit is responsible for the release of C-1 of 
pyruvate as CO2 and the coupling of C-2 to the thiamine pyrophosphate (TPP) group forming a 
hydroxyethyl group (2). Step 2 of this reaction oxidizes the hydroxyethyl group to acetate, 
utilizing the electrons released to reduce the disulfide bond in the lipoyllysine group of E2 (2). 
The acetyl group from this reaction is then esterified to one of the reduced lipoyl sulfides (-SH) 
(2). Next, a transesterification reaction occurs that results in the conjugation of Coenzyme A 
(CoA) to the acetyl group, releasing acetyl-CoA from the complex (2). The E3 subunit of this 
complex is responsible for the regeneration of the lipoyllysine disulfide, accomplished via two 
reactions: 1) the reduced lipoyllysine is oxidized by E3-bound FAD to regenerate the disulfide 
bond and form FADH, and 2) the FADH formed reduces NAD+ forming NADH and reoxidizes 
the E3 subunit (2). The NADH formed by PDH can then donate its electrons to complex I 
yielding ~2.5 ATP (2).  
 
Equation 1.2: 
Pyruvate + NAD+ + CoA-SH à NADH + Acetyl-CoA + CO2 
 
Following its production, acetyl-CoA is condensed with oxaloacetate by citrate synthase 
via a Claisen-type condensation reaction to generate citric acid (2). It is important to note that the 
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initial production of oxaloacetate is produced from pyruvate and a bicarbonate molecule via 
pyruvate carboxylase and is required to prime the Krebs cycle (2). The next step in the cycle 
results in the formation of isocitrate from citric acid through the intermediate formation of cis-
aconitate via the enzyme aconitase (2). This reaction proceeds through a dehydration reaction 
followed by a hydration reaction removing the hydroxy group from C-3 and placing it on C-2 
(2). In the next step, isocitrate dehydrogenase oxidizes isocitrate using the cofactor NAD+ to 
form NADH and the intermediate oxalosuccinate, which undergoes immediate decarboxylation 
to form a-ketoglutarate and release CO2 (2). It should be noted that there are two isoforms of 
isocitrate dehydrogenase present in cells. The NAD+-requiring form in the Krebs cycle is 
localized to the mitochondrial matrix. The other form utilizes NADP+ and is present in both the 
cytosol and mitochondrial matrix and generates NADPH required for reductive reactions, such as 
maintenance of antioxidant systems (2). Next in the cycle, a-ketoglutarate dehydrogenase 
catalyzes the conversion of a-ketoglutarate to succinyl-CoA resulting in the reduction of another 
NAD+ molecule (2). This reaction requires the cofactor CoA and results in the release of CO2 
(2). Succinyl-CoA has a high energy thioester bond and its breakage releases energy that can be 
coupled to the formation of ATP/GTP and results in the formation of succinate and release of 
CoA (2). The enzyme that catalyzes this reaction is succinyl-CoA synthase, of which there are 
two isozymes in animal cells, either specific for ADP or GDP (2). The GTP formed can be used 
to form ATP via nucleotide diphosphate kinase by transferring its electrons to ADP (2). Next, 
succinate is oxidized via succinate dehydrogenase (complex II), which is bound to the inner side 
of the MIM in eukaryotes (2). This reaction results in the formation of fumarate and the 
reduction of an FAD molecule within the succinate dehydrogenase; these electrons passed to 
FAD are then shuttled through iron-sulfur (Fe-S) clusters to the ETC yielding ~1.5 ATP (2). The 
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fumarate formed by this reaction can then undergo a hydration reaction to form L-malate by 
fumarase (2). The last reaction of this cycle is the conversion of L-malate to oxaloacetate 
resulting in the reduction of an NAD+ molecule (2). This reaction proceeds via L-malate 
dehydrogenase and the oxaloacetate formed can then restart the cycle by condensing with a new 
acetyl-CoA molecule (2). 
 
Equation 1.3: 
Acetyl-CoA + 4 NAD+ + FAD + GDP + Pi à 3 CO2 + 4 NADH + 4 H+ + FADH2 + GTP/ATP 
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Figure 1.2: Mitochondrial pyruvate import and Krebs cycle pathway. 
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1.1.3 Lipid Metabolism and b-Oxidation 
 The ability of animals to store fats provided an evolutionary advantage for maintenance 
of energy homeostasis during starvation. While lipid storage is possible in all organisms, 
including prokaryotes, only vertebrates have evolved specialized cells called adipocytes (7). 
Fatty acids are an important source and major form of storage of energy in mammalian 
adipocytes; their richness for energy is attributed to two properties: 1) hydrophobicity, which 
allows the storage of higher quantities of fatty acids in adipocytes, and 2) oxidation of a long 
chain fatty acid, such as palmitate, yields 108 ATP, whereas glucose oxidation produces only 36 
ATP (2). The major product of fatty acid synthesis in mammals is palmitate (16-C chain), which 
is packaged into cells as triglycerides (2). Triglycerides are the combination of 3 fatty acids 
attached to a glycerol backbone and a major characteristic of these triglycerides is their 
hydrophobicity. This hydrophobic nature requires that triglycerides be packaged with proteins 
into a lipoprotein particle to allow its transport in blood.  
In mammals, there are three sources of fatty acids that cells can utilize for fuel. These are 
fatty acids obtained from diet, fatty acids mobilized from adipose tissue stores, and endogenous 
fatty acid synthesis by the liver from precursors such as excess carbohydrates (2). Dietary fatty 
acids are digested and absorbed in the small intestine, involving the secretion of bile from the 
gallbladder and lipases from the pancreas (2). Bile allows the insoluble fatty acids to form 
micelles, thereby increasing the fatty acids’ exposure to water soluble lipases and aiding in the 
breakdown of triglycerides into free fatty acids, monoacylglycerol, diacylglycerol, and glycerol. 
These breakdown products then diffuse into epithelial cells where they become reconstituted into 
triglycerides by acyl-CoA: monoacylglycerol acyltransferase and acyl-CoA: diacylglycerol 
acyltransferase (2). Then these reconstituted triglycerides are packaged with cholesteryl esters, 
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cholesterol, phospholipids, and proteins into lipoprotein particles called chylomicrons, which are 
released into the lymphatic system (2). The proteins in the chylomicron include apolipoproteins 
and aid in transport of lipids in the blood (2). Once these lipid particles travel from the lymphatic 
system into the blood stream, they are carried to either muscle tissue to be used as energy or 
adipose tissue to be stored as fat. Lipoprotein lipase in the capillaries of these tissues is activated 
by apoC-II on the lipoprotein’s surface, resulting in hydrolysis of triglycerides to fatty acids and 
glycerol that can be taken up by cells (2). Muscle tissue oxidizes these fatty acids for fuel while 
adipocytes re-esterify them for storage. The chylomicrons that have been depleted of 
triglycerides still contain cholesterol and apolipoproteins which are carried in the blood to the 
liver (2). These chylomicron remnants are taken up by the hepatocyte (receptor-mediated binding 
to apoE) and the remaining fatty acids are either used for energy or repackaged as very low-
density lipoproteins (VLDL) to be released into the blood and transported to adipose tissue (2). 
Furthermore, it is important to note that hepatocytes have the ability for de novo 
lipogenesis through fatty acid synthase and a malonyl-CoA molecule. This malonyl-CoA is 
derived from an acetyl-CoA molecule and acetyl-CoA carboxylase (2). It is key to emphasize 
here that acetyl-CoA is at the crossroads for both anabolic and catabolic pathways. This 
relationship is tightly regulated to prevent the formation of a futile cycle and allows acetyl-CoA 
to be metabolized when the body requires energy, but diverted for fatty acid synthesis and 
storage when energy demands are met (2). These fatty acids can then be packaged into 
triglycerides and VLDL for release into the blood stream (2). VLDL transports fatty acids to 
tissues in the same manner as chylomicrons, and as they lose triglycerides and apolioproteins, 
they become low-density lipoproteins (LDL) (2). These LDL particles are rich in cholesterol and 
cholesterol esters and responsible for some of the transport of cholesterol to extrahepatic tissues. 
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The removal of LDL from circulation is achieved through the LDL receptor, localized in hepatic 
tissue, that recognizes apoB-100 and through endocytosis engulfs both the LDL particle and 
receptor (2).  
Lastly, adipocytes are the cells responsible for the storage of fats into a lipid droplet 
which is surrounded by perilipins, proteins responsible for containing the lipids (2). The fats 
stored in these droplets can be mobilized for energy when blood glucose becomes low or when 
cells, such as muscle, require excess energy (e.g. during exercise). This mobilization occurs 
through the release of epinephrine and glucagon which activate surface located adenylyl cyclase 
on adipocytes (2). Adenylyl cyclase produces cyclic AMP (cAMP), a second messenger that 
activates cyclic AMP-dependent protein kinase (PKA) (2). PKA then phosphorylates perilipins 
resulting in a conformational change that exposes the lipid droplet to the rest of the cell (2). PKA 
also activates hormone-sensitive lipases that make contact with the lipid droplet releasing fatty 
acids (2). The fatty acids then can pass from the adipocyte into the blood stream where they 
noncovalently bind serum albumin (2). Serum albumin-bound fatty acids can then be transported 
to tissues in which they are released and taken up by plasma membrane transporters (2).  
Once transported into the cell, fatty acids must become activated as fatty acyl-CoA 
molecules and then make their way into the mitochondrial matrix to undergo b-oxidation. This is 
achieved through an outer mitochondrial membrane bound protein, acyl-CoA synthetase, which 
catalyzes the addition of CoA at the expense of one ATP (2). Next, the transport of acyl-CoA 
into the mitochondrial matrix occurs in three steps: 1) a carnitine group is exchanged for the CoA 
group on the fatty acid by the enzyme carnitine acyl transferase-1, 2) the antiporter 
carnitine/acyl-carnitine carrier moves the acyl-carnitine into the matrix in exchange for a 
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carnitine molecule, and 3) carnitine acyl transferase-2 in the matrix exchanges the carnitine 
group for a CoA to regenerate an acyl-CoA molecule (2).  
Once into the matrix, the fatty acyl-CoA undergoes b-oxidation (Figure 1.3). The first 
step involves acyl-CoA dehydrogenase, which oxidizes the fatty acyl-CoA forming a double 
bond between the a and b carbons (2). Oxidation is coupled to the reduction of FAD in acyl-
CoA dehydrogenase. Once formed, FADH2 is oxidized by electron transferring flavoprotein and 
electron transferring flavoprotein oxidoreductase (ETFQO), resulting in the reduction of 
ubiquinone (Q) to ubiquinol (QH2) in the ETC (2). Next, the newly formed enoyl-CoA molecule 
is hydrated by enoyl-CoA hydratase resulting in hydroxylation of the b carbon, forming b-
hydroxylacyl-CoA (2). Then b-hydroxylacyl-CoA dehydrogenase couples the oxidation of b-
hydroxylacyl-CoA to the reduction of NAD+ to NADH (2). The resulting b-ketoacyl-CoA is then 
cleaved in the presence of CoA by thiolase forming acetyl-CoA and an acyl-CoA molecule that 
is now 2 carbons shorter (2). For example, oxidation of palmitate, which contains 16 carbons, 
results in the formation of one acetyl-CoA and a C-14 myristoyl-CoA. Once formed myristoyl-
CoA is subjected to further oxidation until the carbon chain has been fully degraded. For 
palmitoyl-CoA, 7 passes through b-oxidation is required for full degradation to 8 acetyl-CoA, 7 
FADH2, and 7 NADH molecules (Equation 1.4) (2). NADH and FADH2 donate their electrons to 
the ETC resulting in a yield of 28 ATP. The 8 acetyl-CoA molecules can undergo further 
oxidation by the Krebs cycle, resulting in a yield of 80 ATP, making a total of 108 ATP formed 
from palmitoyl-CoA. 
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Equation 1.4: 
Palmitoyl-CoA + 7 CoA + 7 FAD + 7 NAD+ + 7 H2O à 8 acetyl-CoA + 7 FADH2 + 7 NADH 
+ 7 H+ 
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Figure 1.3: Acyl-CoA mitochondrial transport and b-oxidation pathway. 
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1.1.4 Oxidative Phosphorylation 
It is crucial to note that up until this point, the production of electron carriers such as 
NADH and FADH2 through different metabolic pathways has been discussed. These carriers 
neither are used as energy nor generate energy alone, but must donate their electrons to the ETC 
to produce a proton gradient. The action of these electrons “tunneling” down the ETC to 
prosthetic groups with a higher affinity for electrons (higher reducing potential) results in the 
release of free energy (1). This free energy can be coupled to the pumping of electrons from the 
mitochondrial matrix into the intermembrane space (1). Electron donating sites all converge on 
the ubiquinone (Q) pool forming ubiquinol (QH2) before being passed along to complex IV 
resulting in the reduction of oxygen to water (8). 
There are multiple pathways for the donation of electrons to the Q pool. NADH produced 
from the Krebs cycle and b-oxidation donate electrons directly to a flavin mononucleotide 
(FMN) subunit in complex I (NADH dehydrogenase) (1). Complex II (succinate dehydrogenase) 
through the action of converting succinate into fumarate accepts electrons to its flavin adenine 
dinucleotide (FAD) subunit (1). Other entry points into the Q pool include ETFQO, containing 
one FAD molecule and one Fe-S cluster, which has the capacity to accept electrons from many 
flavin-containing dehydrogenases, some of which catalyze the unsaturation step in b-oxidation 
(1,9). Two sites oriented towards the cytoplasm are s,n-glycerophosphate dehydrogenase and 
dihydroorotate dehydrogenase; the former is responsible for accepting electrons from 
cytoplasmic NADH, such as those created during glycolysis, and the latter is involved in 
pyrimidine biosynthesis (1).  
 A more detailed description of the pathway of electron “tunneling” is as follows. At 
complex I, NADH is oxidized by FMN, passing the electrons through 7 Fe-S clusters to 2 
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protein-bound semi-quinone molecules into the Q pool (8). Additionally, complex I is the largest 
mammalian ETC enzyme with 45 subunits (8). In complex II, succinate binds subunit A reducing 
FAD, then these electrons pass through 3 Fe-S clusters to ubiquinone (2). The electrons from 
ETFQO, s,n-glycerophosphate dehydrogenase, and dihydroorotate dehydrogenase are all passed 
to Q to reduce it to QH2 requiring a 2 electron transfer (1). The reduction of complex III 
(ubiquinol-cytochrome c oxidoreductase) is performed by the Q-cycle, which involves the cyclic 
oxidation and reduction of QH2/Q (1). This is accomplished through the transfer of a single 
electron to the Rieske Fe-S center which is then passed to cytochrome c1 (2). Cytochrome c1 then 
passes an electron to cytochrome c which dissociates from complex III and moves to complex IV 
(2). Complex IV receives 2 electrons from 2 cytochrome c molecules to reduce its binuclear 
center (2 Cu ions complexed with 2 Cys-SH groups) (2). Electrons then pass from heme a, to the 
heme a3-Cu center (2). Oxygen then binds heme a3 and is reduced to O22-, which gets converted 
to 2 H2O molecules with the passage of 2 more electrons (2). It should be noted that complex I 
pumps 4 protons across the membrane, complex III pumps 2, and complex IV pumps 4; these 
reactions are coupled to the release of free energy from the passing of electrons (1). 
 With the transfer of protons from the mitochondrial matrix into the intermembrane space, 
there is the generation of an electrochemical gradient, with the electrical gradient being the 
dominant component (1). Some proteins have the ability to tap into this potential energy to 
overcome unfavourable reactions such as the capacity of complex V (ATP synthase) to produce 
ATP. Complex V is composed of 2 subunits, Fo and F1; the Fo subunit is membrane-bound and 
allows proton conductance back into the matrix (2). This is coupled to the rotation of subunit F1 
which binds ADP and Pi producing ATP (2). It is the three b subunits of F1 that are responsible 
for the synthesis of ATP. While each of these subunits have the same amino acid sequence, it is 
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the conformation of these sites around the g subunit, connected to F1, that is attributed to their 
differences (2). As protons are passed through Fo down their gradient, the energy released is used 
to rotate this subunit along with the g stalk, which passes through the 3 alternating a and b 
subunits (2). As the g subunit turns, it is associated with only one of the three b subunits, 
changing it to the b-empty confirmation, releasing ATP from the complex (2). The other 2 
neighbouring b subunits either retain a b-ADP confirmation (binds ADP and Pi) or a b-ATP 
confirmation (tightly binds and stabilizes ATP) (2). As the g rotates 120o, each of these subunits 
changes its conformation resulting in rotational catalysis of ATP (2). This ATP is then released 
into the cytoplasm for endergonic reactions through the adenine nucleotide transporter (ANT) in 
exchange for an ADP molecule entering the matrix (2). 
Complex V is not the sole path protons can take to travel back into the matrix. Another 
important use of this gradient is the symport of phosphate ions as H2PO4-, with H+, to provide 
phosphate ions for the generation of ATP (1). Uncoupling proteins (UCP) also leak protons back 
into the matrix; for example, UCP1 (thermogenin) is responsible for thermogenesis in brown fat 
tissue, by coupling proton return to heat production (1). Another example of proton conductance 
back into the matrix is the formation of NADPH from NADH by nicotinamide nucleotide 
transhydrogenase (NNT), a reaction coupled to the return of protons through the protein (10).  
1.2 Reactive Oxygen Species 
1.2.1 Formation and sites of production 
Reactive oxygen species (ROS) is a broad term that encompasses all oxyradicals and non-
radicals, with a free radical defined as any molecule with 1 or more unpaired electrons (11). 
Molecular oxygen is a unique molecule as it has 2 unpaired electrons in its outer shell with the 
same electron spin quantum number, making it a bi-radical (11). Additionally, this property only 
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allows the transfer of one electron at a time to O2 requiring it to pass through superoxide (O2•- ), 
allowing for the formation of hydrogen peroxide (H2O2) or the hydroxy radical (•OH) (9). ROS 
are known by-products of oxidative phosphorylation, but it should be noted that cytosolic 
sources such as NAD(P)H oxidases are also a significant ROS source (12). About 0.1 – 0.5% of 
electrons that are passed through electron carrying sites in mitochondria are leaked (Figure 1.4) 
(13). The specific amount is determined by factors such as the concentration of the reduced 
electron donor, concentration and type of substrate being oxidized, post-translational 
modifications, allosteric regulators, NADH availability, proton gradient, and the rate constant for 
the leak reaction (10,13).  
ROS-producing sites have the ability to produce both O2•- and H2O2, which depends on flavin 
chemistry and how it reacts with di-oxygen (9). If a single electron is leaked to oxygen, then O2•- 
is formed, while if a pair of electrons are released together, then H2O2 is formed (14). Although 
O2•- was once considered the principal ROS formed by mitochondria, recent work has found 
H2O2 accounts for up to 75% of the ROS generated by sites of production (15). However, O2•- is 
formed nonetheless and must be rapidly cleared to preserve Fe-S cluster assemblies in 
mitochondria (9). Therefore, any O2•- formed is rapidly converted to H2O2 by superoxide 
dismutase (SOD). Thus, the dominant form of ROS generated by mitochondria is H2O2, 
occurring at a concentration in the nanomolar range compared to the picomolar range for O2•- 
(4).  
To maintain a steady state concentration of ROS in the cell, there is constant regulation of its 
production and degradation. This allows the cell to maintain a redox homeostasis or the “golden  
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Figure 1.4: Sites of ROS production and carbon metabolism.  
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mean” as it is referred to in one such review, dispelling the notion that ROS is completely 
detrimental and instead, that the cell is in constant redox flux (16). Current research in the field 
has demonstrated that mitochondria can contain up to 12 sites of ROS production associated with 
fuel oxidation and the ETC (Figure 1.5). These sites are sub-categorized based on whether or not 
ROS genesis is linked to the oxidation and reduction of NAD or Q, the NADH/NAD+ and 
QH2/Q isopotential groups (10). The sources associated with the NADH/NAD+ isopotential 
group include PDH, branched-chain keto acid dehydrogenase, 2-oxoadipate dehydrogenase, 
complex I (FMN site), and KGDH (10). Sources from QH2/Q include complex I (Q binding site), 
complex II, complex III, ETFQO, s,n-glycerol-3-phopshate dehydrogenase, proline 
dehydrogenase, dihydroorotate dehydrogenase (10).  
While all of these sites do contribute to overall mitochondrial ROS release into the cell, the 
individual contributions of these generators to total ROS produced can vary between tissue type 
and mouse strain. Indeed, this has been documented between C57BL/6N and C57BL/6J mice 
with the major sites being KGDH, PDH, and succinate dehydrogenase, respectively in 6N mice 
while, the major sources in 6J mice were 3-methyl-2-oxopentanoic acid, KGDH, and proline 
dehydrogenase, respectively (17). Similarly, our group has found that complex I and III are 
crucial for the production of ROS in cardiac mitochondria while KGDH and complex III are 
chief production sites in liver (18,19). The Brand lab has additionally shown that mitochondria 
from rat skeletal muscle produces O2•-/H2O2 from complex III at twice the rate of any other site 
(13). This group has profiled production sites under different substrate oxidation finding orders 
of magnitude difference in sites of production (13,20).  
With the discovery that H2O2 is an important intracellular signal transducer, the definition of 
oxidative stress had to be broken down into two categories: oxidative eustress and oxidative 
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distress. Oxidative eustress denotes a physiologically meaningful stress that serves a regulatory 
function (21). In this case, small but controlled bursts of H2O2 production results in the selective 
oxidation of cysteine switches on proteins, eliciting a change in cell behaviour (21). In contrast, 
oxidative distress is associated with excessive ROS production, which overwhelms antioxidant 
defenses and induces the non-selective oxidation of macromolecules, culminating with cell death 
(21). It should be noted that there is no fine line between oxidative eustress or distress, but 
instead a grey area that includes inflammation that could be considered beneficial or harmful to 
the cell (21).  
Oxidative distress occurs when there is an imbalance between ROS production and 
degradation by antioxidants (21). This leads to toxic levels of oxidants that can oxidize lipids, 
DNA, and proteins leading to apoptosis (22). For example the base guanine is susceptible to 
oxidation resulting in 8-oxoguanine, causing mutations due to mispairing (23). Furthermore, 
lipid peroxidation results in lipid hydroxides such as 4-hydroxynonenal which are cytotoxic, 
linking them to pathological conditions (24). Proteins also have the potential for oxidation of 
their thiol groups, leading to their irreversible oxidation and loss of function (25). This has 
provided evidence for the foundation of the mitochondria theory of aging, in which some experts 
argue irreversible oxidation is the basis for human aging (25). Indeed, aging skeletal muscle 
mitochondria are marked by a decrease in ATP production and increase in oxidative stress, 
related to loss of muscle with aging (26). However, treatment of aged mice with SS-31, resulting 
in decreased oxidative stress and increased mitochondrial bioenergetics, leads to improved 
muscle function (26).  
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1.2.2 Hydrogen Peroxide Signalling 
Hydrogen peroxide is now classified as a mitokine linking it to cellular signalling pathways. 
One of the best characterized signalling properties of H2O2 is the regulation of transcriptional 
factors. For example hypoxia-inducible factor-1a has been shown to require H2O2 originating 
from complex III to become stabilized and induce genes to enhance survival during hypoxia 
(27).  Additionally, it has been demonstrated that H2O2 can affect the rate of transcription of 
activator protein-1 and tumor protein 53, while increasing the translation rate of NF-E2p45-
related factor 2 (Nrf2) and specific protein 1 (21).  
In the case of the Nrf2 pathway, increased stimulation of transcription is thought to occur due 
to stimulation of eukaryotic initiation factor 4F complex (eIF4F) phosphorylation through 
oxidation of Ser209 by H2O2 (28). H2O2 also has the capacity to oxidize Kelch-like ECH-
associated protein 1 (KEAP1) preventing its binding to Nrf2 and preventing KEAP1 from 
initiating its ubiquitination and degradation (28). The upregulation of the Nrf2 pathway leads to 
increased antioxidant expression and the quenching of ROS. Additionally, high levels of ROS 
are indicative of oxidative damage in muscle, while pulsatile release of ROS due to repeated 
contractions is crucial for the adaptive and beneficial aspects of exercise (29). It is important to 
note that H2O2 has been linked to signalling via S-glutathionylation and is thought to prime these 
reactions by forming sulfenic acid (SOH), that can undergo spontaneous S-glutathionylation 
(discussed later) (4). Indeed, it has been found that metabolic stress in macrophages induces an 
increase in S-glutathionylation of up to 100 proteins and of these, 94 of them are S-
glutathionylated by the addition of H2O2 (30). 
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1.3 Antioxidant Systems 
Hydrogen peroxide plays a vital role as a secondary messenger but like any other signalling 
molecule, its levels need to be tightly regulated. This is crucial since it needs to be produced 
rapidly to change cell behaviour in response to environmental cues and then degraded thereafter 
to desensitize the signal. Additionally, its levels need to be tightly controlled since it can induce 
cell damage and apoptosis. The degradation of H2O2 and other ROS is facilitated by antioxidant 
defenses.  
1.3.1 Peroxiredoxin  
There are two main thiol-dependent antioxidant systems in mammals, the first being the 
thioredoxin (TRX)/peroxiredoxin (PRX) system and the other being the glutathione (GSH) 
system. The PRX system has the ability to remove H2O2, hydroperoxides (ROOH), and 
peroxynitrite utilizing a series of thiol disulfide exchange reactions (31). These reactions proceed 
by the PRX thiolate cysteine (Cys), in its active site, nucleophilicity attacking H2O2 via a SN2 
reaction yielding a SOH and H2O (31). The C-terminal resolving Cys is then attacked by the 
SOH to form a disulfide bond, rendering PRX inactive (31). The intermolecular disulfide bridge 
in PRX is then reduced through a thiol disulfide exchange reaction with TRX, reactivating PRX 
(31). This deactivates TRX through the formation of a disulfide bridge which is then reduced by 
thioredoxin reductase (TR) utilizing the reductive power stored in NADPH (31). PRX/TRX 
systems are present in both the cytosol and matrix with the matrix-localized isoforms being 
PRX3 and PRX5, which catalyze reactions at 2 x 107 M-1s-1 and 3 x 105 M-1s-1 respectively (10). 
The reducing power of this system in the mitochondrial matrix comes from TXR2 and TR2 (10). 
It is important to note that TRX1 and 2 knockout is embryonically lethal in mice, demonstrating 
its important for cellular survival (32). Additionally, this system does not operate in isolation but 
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has been shown to crosstalk with the GSH antioxidant system due to is capability to reduce 
glutathione disulfide (GSSG) (32). GRX2 has also been observed to reduce TRX2 and its 
cytosolic isoform TRX1, an important discovery as TR is sensitive to inactivation by oxidation 
(32).     
1.3.2 Glutathione 
 The GSH system has two distinguishing factors that make it a significant antioxidant 
system, the first being the high concentration it maintains in its reduced form and the second 
being the 1:2 ratio of GSH to glutathione disulfide (GSSG). Glutathione (also referred to as g-L-
glutamyl-L-cysteinylglycine) has a unique g-carbonyl bond between the glutamate and cysteine 
making it resistant to most peptidases except g-glutamyltranspeptidase (33). The synthesis of 
GSH follows a two-step reaction with ATP required for both enzymatic steps: 1) g-
glutamylcysteine is formed from glutamate and cysteine by glutamate-cysteine ligase, also 
referred to as the rate-determining step 2) GSH is formed from g-glutamylcysteine and glycine 
with the help of glutathione synthase (33).  
This system’s ROS-quenching potential relies on the activity of two enzymes, glutathione 
peroxidase (GPX) and glutathione reductase (GR) along with NADPH as a cofactor. Key 
enzymes that contribute to maintaining the NADPH pool include malic enzyme, glutamate 
dehydrogenase, isocitrate dehydrogenase-2, NADH kinase, glucose-6-phosphate dehydrogenase, 
and nicotinamide nucleotide transhydrogenase (4). The reaction is initiated by the oxidation of 
the selenocysteine active site of GPX by H2O2, forming a selenic acid (SeOH) (4). This selenic 
acid group can then react with GSH forming a selenenyl-glutathione sulfide (Se-SG) which can 
further react with another GSH molecule to form a GSSG and return the GPX active site back to 
its reduced form (4). In order to regenerate the GSH, NADPH is utilized by GR to reduce the 
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GSSG back into 2GSH. The capacity of glutathione to act as a major mitochondrial redox buffer 
comes from the high GSH: GSSG ratio (~50-100) (22). The role of glutathione can be 
emphasized by dysfunction of glutamate-cysteine ligase, which when downregulated, results in 
hemolytic anemia, aminoaciduria, and spinocerebellar degeneration (34). Additionally the 
deletion of the gene that produces the catalytic subunit of glutamate ligase is embryonically 
lethal (34).  
1.3.3 Other quenching systems  
Two additional enzymes that are responsible for the removal of ROS are SOD and catalase. 
The SOD system works in conjunction with a metal enzyme to catalyze the reduction of 2O2•- to 
O2 and H2O2 through a two-step reaction at a rate of 1.8x109 M-1s-1 (35). The rate of this reaction 
coincides with the rate of diffusion therefore rapidly removing O2•- from the cell medium and 
making it difficult to quantify.  
 
Equation 1.5: 𝟐𝑶𝟐∙$ + 𝟐𝑯' 	→ 𝑯𝟐𝑶𝟐 +	𝑶𝟐 
 
The isoforms of SOD differ by the metal enzyme that they bind, with MnSOD present in the 
mitochondrial matrix and Cu/ZnSOD present in the cytosol (36). The importance of SOD can be 
displayed through the deletion of either MnSOD or Cu/ZnSOD. Indeed, deletion of MnSOD in 
mice leads to mortality within 10 days of birth with symptoms of dilated cardiomyopathy, 
metabolic acidosis, and increased lipid deposition in liver and muscle tissue (37). Whereas the 
deletion of Cu/ZnSOD is not lethal but leads to age-related pathologies such as accelerated 
Alzheimer’s disease, muscle atrophy, and infertility (38). 
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Figure 1.5: Antioxidant clearance of mitochondrial H2O2.  
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 Catalase is thought to be a less significant antioxidant system by having a lower binding 
affinity than the other systems and playing a role only when ROS levels become high or another  
system has been compromised (39). Indeed, it has be shown that catalase plays an important role 
for ROS quenching in liver and heart mitochondria (19,39). This system relies on a heme 
prosthetic group for the reduction of H2O2 and therefore do not require a NADPH molecule for 
the regeneration of the reduced form. 
 
Equation 1.6 (21): 
(1) Catalase-Fe3+ + H2O2 à Catalase-FeO3+ + H2O 
(2) Catalase-Fe3+ + H2O2 à Catalase-Fe3+ + O2 + H2O 
or 
Catalase-FeO3+ + AH2 (Hydrogen donor) à Catalase-Fe3+ + A + H2O 
 
1.4 Protein S-glutathionylation  
1.4.1 Reversible Reactions 
As noted above, glutathione is a major antioxidant molecule that is required to safeguard 
cells from oxidative distress through the elimination of H2O2 and various electrophiles. However, 
glutathione also has the capacity to regulate protein functions. This is achieved through protein 
S-glutathionylation, a ubiquitous and reversible redox modification that involves the conjugation 
and removal of glutathione to and from a protein cysteine residue. These reactions can either be 
spontaneous or enzyme mediated (Figure 1.6). The spontaneous modification of protein cysteine 
thiols can occur by three mechanisms: 1) ionization of a protein thiol to a thiolate anion, which 
then nucleophilically attacks glutathione, 2) oxidation of a protein thiolate anion to a SOH by 
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H2O2 which can then nucleophilically attack glutathione, and 3) the formation of a thiyl radical, 
can proceed to form a protein thiyl radical-glutahionyl intermediate which can be resolved in the 
presence of O2 to S-glutathionylation (4). However, spontaneous reactions are not typically 
favourable since most protein cysteine thiols have an equilibrium constant ~1 while the GSH: 
GSSG pool in the mitochondrial matrix is typically held at ~100 (4). There are exceptions to this 
such as C-Jun which has an equilibrium constant of ~15 allowing spontaneous glutathionylation 
to occur much more easily (4). Additionally, the pH of the mitochondria matrix is slightly 
alkaline, which promotes thiolate formation; therefore, during times of oxidative stress, this 
increases the likelihood of S-glutathionylation (40). Nevertheless, with all of these factors, 
spontaneous reactions are still very rare or occur under non-homeostatic conditions, such as 
during oxidative distress (4). 
The enzyme-mediated reactions proceed by the action of GRX, for which there are two 
isoforms that carry out reactions. The isoform localized to the cytoplasm and mitochondrial 
intermembrane space is GRX1, while the GRX2 isoform consists of 3 sub-types: GRX2a, 
GRX2b, and GRX2c (4). The GRX2a isoform is localized to the mitochondrial matrix and 
GRX2b/GRX2c are localized to the nucleus, exclusively in testes (4). It is important to note the 
key differences that exist between GRX1 and GRX2. Firstly, GRX1 has only been shown to 
participate in deglutathionylation reactions with glutathionylation of proteins via GRX2 isolated 
to the mitochondrial matrix (4). Secondly, GRX2 is coordinated through a 2 Fe-S cluster to keep 
it in an inactive form; it is only upon disassembly by O2•- that the enzyme becomes active (41). 
As mentioned above, GRX2 also has the capacity to reoxidize TRX2 (32). While GRX1 and 
GRX2 have low homology with each other, common between them is the active site motif, 
CXXC, which is responsible for its thiol-disulfide exchange reaction. This reaction progresses in 
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two steps: 1) the N-terminal active site thiolate nucleophilic attacks the sulfur of the 
glutathionylated protein (PSSG), forming a GRX-SSG intermediate and releasing a reduced 
protein (PSH), and 2) a free GSH molecule can then attack the glutathionylated GRX and resolve 
it back to its reduced form and release a GSSG (40).  
Alternatively, since this reaction is reversible, the GRX should theoretically 
glutathionylate proteins as well, for which evidence shows that GRX2 does proceed in this 
direction, but whether GRX1 does is still unknown (4). The catalytic cycle for which GRX2 
completes this reaction requires firstly that the glutathione pool be in an oxidized state, through 
the quenching of H2O2 (42). The reaction commences with the addition of a GSH to one of the 
catalytic GRX2 cysteine residues, then through a thiol-disulfide exchange reaction, the GSH is 
conjugated to the target protein cysteine (42). This reaction proceeds via an SN2 mechanism and 
is regulated through the ratio of GSH: GSSG, with a high ratio favouring the forward reaction 
and a low ratio favouring the reverse (4,42). This enzyme-mediated reversibility, along with 
being rapid, responding to the redox state of the cell, changing protein function, and there being 
specific protein motifs for this modification make S-glutathionylation a valid post-translational 
modification (4). As termed by Dean Jones, the capacity of S-glutathionylation to respond to the 
redox environment to modify and adapt protein function makes it a component of the redox 
code; allowing it to control “redox switches” in response to physiological cues such as high 
levels of H2O2 (43). It should be noted that in the cytosol and endoplasmic reticulum, glutathione 
S-transferase is responsible for catalyzing the addition of glutathione to target proteins (40,44). 
1.4.2 Modulation of Respiratory Complexes  
The respiratory complexes have multiple motifs for S-glutathionylation, one of the first 
discovered being complex I. It has since been found that there are 12 sites in complex I that can 
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undergo S-glutathionylation in response to the redox status of the glutathione pool (4,45). This 
modification has been discovered to occur in lens epithelia, heart, and muscle tissue as an 
adaptive response to increased ROS production, protecting the complex against irreversible 
oxidative damage (4). Two of the known sites of modification are the 51 kDa subunit that 
contains the NADH binding site and the 75 kDa subunit (45). S-glutathionylation of the 51 kDa 
subunit has been shown to occur on Cys531 and Cys704 reversibly by GRX2 (4). S-
glutathionylation of complex I was found by the Murphy group to decrease its activity and 
increase O2•- emissions (45). Additionally, it has been found that S-glutathionylation of this 
complex reduces the ATP producing ability of these mitochondria (18,41). 
In brain and liver mitochondria, it has been shown that complex V can be S-
glutathionylated, reducing its ATP producing potential (46). This modification occurs on the a-
subunit of the F1 complex and is increased during fatiguing exercise (45,47). Furthermore, 
increases in oxidative stress in cardiac tissue, such as during heart failure, increases S-
glutathionylation of complex V (48). Increased S-glutathionylation has a direct effect on 
dysregulation of complex V in cardiac tissue and cardiac resynchronization therapy has shown to 
reverse this (48). Complex II is unique as it is S-glutathionylated in its native state (49) The 
activity of complex II has been directly linked to the glutathionylation state of Cys90 in its 70 
kDa flavin binding subunit (49). In the case of this complex it becomes basally S-
glutathionylated to increase electron transfer efficiency and decrease electron leak from the 
complex (49). It was found that deglutathionylation of this complex can predispose it to 
oxidative stress in post-ischemic hearts (49).  
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1.4.3 Krebs Cycle 
The Krebs cycle represents a major regulatory point for carbon metabolism and therefore 
requires fine-tuned regulation to ensure it maintains homeostasis in the cell. Many of the 
enzymes in this pathway are regulated by S-glutathionylation such as PDH, KGDH, isocitrate 
dehydrogenase, aconitase, succinyl-CoA transferase, malate dehydrogenase, and complex II 
(discussed above).  
Two of the most studied of these enzymes are PDH and KGDH since they act as 
regulatory points in metabolic pathways due to the irreversibility of their activities. PDH is 
important for the commitment of pyruvate to acetyl-CoA and KGDH allows the entry of amino 
acid catabolism into the Krebs cycle (2). KGDH was first thought to be S-glutathionylated on its 
E2 subunit as a protective effect against irreversible oxidation by H2O2, with deglutathionylation 
restoring its activity when H2O2 was quenched (50). Further studies have concluded that S-
glutathionylation not only plays a protective role for KGDH but regulates the enzymatic activity 
of both PDH and KGDH (51,52). Not only are KGDH and PDH sensitive to ROS they also are 
key sources, with PDH and KGDH producing 4x and 8x more ROS then complex I, respectively, 
in skeletal muscle (53). Both KGDH and PDH can undergo reversible modification by GRX2 in 
the E2 subunit and this modification influences their ROS production (51,52). Chemical 
induction of S-glutathionylation of KGDH and PDH was shown to diminish O2•-/H2O2 
production by ~90% under conditions of forward electron transfer but amplify production during 
reverse electron transfer (52). The role of S-glutathionylation with respect to these enzymes is 
tissue specific as deletion of GRX2 results in a decrease of O2•-/H2O2 production in liver 
mitochondria but an increase in cardiac mitochondria (18). 
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S-glutathionylation is also linked to a 35% decrease in activity of aconitase due to S-
glutathionylation of Cys126 and Cys385 close to its active site (54). While isocitrate 
dehydrogenase-2, succinyl-CoA transferase, and malate dehydrogenase have all been found to be 
S-glutathionylated, there is still debate on whether this alters their activities (4). Evidence exists 
to suggest that malate dehydrogenase is S-glutathionylated in skeletal muscle during fatiguing 
exercise (47). While isocitrate dehydrogenase-2 and succinyl-CoA transferase have both been 
shown to be sensitive to S-glutathionylation in brain tissue (48). 
1.4.4 Solute Import and Proton Leak 
As the MIM is only selectively permeable, it has an abundance of protein carriers to 
facilitate movement of substrates and molecules such as ATP and ADP in and out of the matrix. 
It is then no surprise that these proteins can be modified to regulate the uptake of substrates by 
mitochondria and that S-glutathionylation has been shown to be one of these regulatory 
measures. Indeed, a previous study in our lab showed that induction of S-glutathionylation was 
able to modulate mitochondrial pyruvate carrier 1 (MPC1) (41). In that study, chemical induction 
of S-glutathionylation via disulfiram was able to significantly decrease the pyruvate uptake in 
these mitochondria (41). In the same study, it was investigated if carnitine/acylcarnitine carrier 
(CAC) could undergo the same regulation. While our recent study was unable to show this result, 
a previous group had shown S-glutathionylation of Cys136 and Cys155 of CAC could be S-
glutathionylated and could limit the activity of this transporter (55). 
Another important group of proteins imbedded in the MIM that are S-glutathionylated 
include the uncoupling proteins (UCP). UCP2 is found in a variety of tissues and UCP3 is 
isolated to muscle and brown adipose tissue (56). These proteins facilitate the movement of 
protons back into the matrix, by-passing complex V, which uncouples the proton gradient from 
 36 
ATP production. As indicated above, the strength of the potential of protons experienced across 
the MIM can have a powerful impact on the rate of mitochondrial ROS production. Indeed, O2•-
/H2O2 generation has a non-Ohmic relationship with the proton gradient where a small increase 
in the PMF can induce a large increase in ROS production (4). The Brand lab were the first to 
propose the concept of UCP regulated by cellular redox changes, finding evidence that 4-
hydroxy-2-nonenal and O2•- induced proton leaks through these proteins (57,58). However, these 
results could not be duplicated (56). It was later discovered that UCP2 and UCP3, but not UCP1, 
can be S-glutathionylated on Cys283 and Cys259 respectively, which are both located in the last 
loop region exposed to the mitochondrial matrix (4). These residues are surrounded by positively 
charged amino acids which makes them more amenable towards modification by S-
glutathionylation (56). Surprisingly, when there is an increase in ROS, UCP3/2 become 
deglutathionylated and subsequently activated (56). In the case of UCP3, this diminishes the 
proton gradient and is thought to diminish ROS production (56). A recent study in our lab found 
that in the case of mice deficient in GRX2, there was a ~2-3 fold increase in proto   n leak-
dependent respiration that was due to increased activity of UCP3 and ANT (59). While mice 
with deletion of Grx2 additionally show increased mitochondrial respiration, correlating to 
increases in UCP3-dependent proton leaks (60).  
Another important solute anion carrier protein, ANT, also contains a modifiable cysteine 
in the last loop region and has been shown to be S-glutathionylated (4). ANT not only is 
responsible for the exchange of ADP for ATP at the MIM, it is thought to be a key in the 
assembly of the mitochondria permeability transition pore, resulting in apoptosis (61). There is, 
however, little knowledge on the effect of glutathionylation on ANT activity. A study by Queirga 
et al. determined that low levels of S-glutathionylation of ANT increased its ADP/ATP 
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translocase activity and prevented inner membrane permeability (62). Additionally, it has been 
recently found that in GRX2 deficient mice ANT’s uncoupling activity is upregulated (59). This 
finding, along with leaks due to UCP, were found to be responsible for increased mitochondrial 
respiration and protection from DIO, indicating a link between weight gain and S-
glutathionylation (59). This link is further supported by the evidence that liver and peri-renal 
adipose tissue from obese rats have significantly reduced protein S-glutathionylated content (63).   
1.4.5 Other Protein Regulation  
Protein S-glutathionylation reactions have the ability to govern fission and fusion of  
mitochondria, having a direct impact on metabolism and cell survival (64). The fusion of 
mitochondria can be induced due to cell stress and is shown to increase mitochondria efficiency 
(65). The regulation of mitochondrial fusion is achieved by specific GTPases, mitofusion 1 and 2 
located in the mitochondrial outer membrane and autosomal dominant Optic Atrophy 1 located 
in the MIM. It has been shown that oxidized glutathione results in the fusion of mitochondria and 
that Cys684 of mitofusion 2 is the possible cysteine responsible for this reaction (65). 
Furthermore, a study found that addition of diamide, a S-glutathionylation catalyst, induced 
mitochondrial hyperfusion (66). 
Furthermore, S-glutathionylation plays a vital role in skeletal muscle physiology, which 
can be underscored by a recent proteomic study that revealed ~2200 sites of modification in muscle 
and increased modification of 1290 of these sites after fatiguing exercise (47). Key sites involved 
in muscle contraction included ryanodine receptor-1, sarco/endoplasmic reticulum Ca2+-ATPase-
1 (SERCA), and titin (47). SERCA is a crucial Ca2+ pump that is responsible for relaxation of 
smooth, cardiac, and skeletal muscle. It has been shown that S-glutathionylation of Cys674 results 
in an increase of Ca2+ uptake and therefore muscle recovery from contraction (29). Titin is made  
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Figure 1.6: (A) Non-enzymatic S-glutathionylation reaction. (B) Grx2 medicated S-
glutathionylation reaction.  
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up of folded immunoglobulin domains in its I band, all of which contain cysteine residues (67). It 
was found that the two cysteine residues in I91 are S-glutathionylated when they are in the 
unfolded state, preventing the band from refolding and increasing the elasticity of titin in cardiac 
tissue (67).  
1.5 Metabolic Syndrome 
The estimated economic burden of obesity in Canada is approximately 7 billion dollars, 
with half the population classified as either overweight or obese (68). Surveys in 2016/2017 from 
Statistics Canada indicates that 34% of Canadians are overweight with 27% classified as obese 
(69). Of all Canadians, Newfoundland and New Brunswick have the highest prevalence of 
overweight in the population at 38%, trends that are rising (69). Metabolic syndrome is defined 
by an accumulation of factors such as insulin resistance, hypertension, hepatic steatosis, 
dyslipidemia, glucose intolerance, and hyperinsulinemia, all of which result from an increase in 
adipose tissue (70). The World Health Organization (WHO) has officially classified metabolic 
syndrome as a world-wide epidemic.  
For early mammals there was an evolutionary push to create modes of energy storage and 
more efficient mechanisms for ATP production. Those organisms who could survive longer 
without food and produce energy more efficiently would have had an evolutionary advantage. It 
is only in recent decades of human history that we see a shift from food scarcity to food surplus 
in developed countries. In today’s Western society, technological advances have come with 
processed food and an ability to live sedentary lifestyles. This has led to an alarming amount of 
the population having a positive energy balance, leading to progression of obesity. As obesity is 
a form of low-grade inflammation, it has many adverse effects such as insulin resistance, type 2 
diabetes mellitus, and atherosclerosis (71). More alarming is the fact that the current gold 
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standard of treatment for obesity is caloric restriction and exercise which has highly variable 
outcomes, as some individuals demonstrate resistance to weight loss and a tendency to regain 
their lost weight. 
The result of an increase in nutrient supply to cells can alternatively lead to oxidative 
stress and progress to mitochondrial dysfunction (71). Indeed, it has been documented that 
obesity leads to oxidative stress (72). One such example is the finding that DIO leads to elevated 
levels of ROS in brain tissue in mice, leading to cognitive impairments (73). This now leads into 
the concept of mitochondrial dysfunction, which is another adverse effect of obesity, and in this 
context is defined as the maladaptive response of mitochondria to a surplus of nutrients (71). 
These dysfunctions can range from oxidative stress inducing mitophagy and decreasing 
mitochondria populations, to alterations in mitochondrial function such as lower energy 
generation capacities, less defined internal membranes, and lower fatty acid oxidation (71). It 
should be emphasized that these adaptations led to the further progression of obesity.  
Furthermore, a surplus of nutrients can cause metabolic gridlock. In normal 
mitochondria, there is a constant switch between the selection of fuel to be used (70). This is 
defined as fuel portioning and is usually measured by the respiratory quotient (RQ) which 
usually ranges from 0.7-1.0 (70). Mitochondria are the organelle responsible for this fuel 
selection and typically oscillates between 0.7 (preference for fat oxidation) to 1.0 (preference for 
glucose oxidation) depending on circulating insulin levels (70). With the development of obesity, 
an inflexibility in this fuel selection was shown in a study by Kelley et al., in which muscle from 
obese individuals showed resistance of the RQ when infused with insulin (74).        
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1.6 Sexual Dimorphisms  
Early research lacked the insight to account for biological differences between sexes and 
instead research in male subjects was extrapolated to females. This flawed experimental design 
has led to a knowledge gap and the emergence of sex-specific claims. One example of the 
consequences of this blind spot are drugs like Zolpidem (sedative for insomnia), which dosage 
was found to result in twice the drug level in women due to differences in metabolism (75). The 
growing awareness of this issue in the scientific community can be seen by the funding of an 
Office of Women’s Health by the FDA, which advocates for the participation of women in 
clinical research (75).  
It is important to differentiate between a sex difference and gender difference. Sex 
differences are a direct result of the chromosomal identity of the organism, whereas gender 
differences are due to the cumulating factors of sex chromosome, sex hormone, and epigenetic 
interactions with the environment (76). It is therefore difficult to isolate these differences in a 
biological study and therefore in most cases, a sexual dimorphism is defined as a difference 
between a female or male organism, not differentiating whether its origin is sex- or gender-
related (76). It is likely that it is a summation of all these factors that produces the sex-specific 
effects observed in organisms and herein, all reference to sexual dimorphisms will encompass 
the definition above.   
The secretion of hormones likely plays a major role in sex differences in biology. One such 
study in skeletal muscle mitochondria points to elevated levels of 17-b estradiol to distinguish 
the differences observed in female mitochondria (77,78). Alternatively, it has been established 
that differences in the secretory patterns of growth hormone in rats and mice control sexual 
dimorphisms in liver gene expression (79). Indeed, the pulsatile release of growth hormone has 
 42 
been established to regulate signal transducer and activation of transcription 5 (STAT5), a 
transcriptional regulator (79). Females exhibiting a slow steady rate of growth hormone secretion 
while male mice show a cyclic pulsatile release that may explain differential expression of genes 
between sexes and females’ preference for oxidation of fatty acids (79). Furthermore, a study by 
Holloway et al. was able to determine that human female skeletal muscle mitochondria have 
decreased ADP sensitivity and greater sensitivity of CPT1 to inhibition by malonyl-CoA (80). 
This difference was determined to be due to differences in protein activity and not abundance of 
mitochondrial proteins (80).  
It is important to note that mitochondria are maternally inherited and therefore the mtDNA is 
asymmetrically inherited. As a result, mtDNA has spent more time under natural selection in a 
female biological environment and is likely more equipped to function in females (81). With 
respect to mitochondrial bioenergetics, there have been definite sex dimorphisms observed. 
Indeed, it has been shown that women have more of a preference for fatty acids over 
carbohydrates and reduced AMP-activated kinase activity than males when exercising (82,83). 
Additionally, females display higher activities of Krebs cycle enzymes, such as citrate synthase 
and succinate dehydrogenase (81). In a study by Cardinale et al., female and male human 
skeletal muscle mitochondria were directly compared. In this study, it was determined that 
women could produce the same rate of respiration as matched males, but with less mitochondria 
(84). This finding was attributed to female mitochondria having higher intrinsic respiration (84). 
The same study was also able to conclude that women had a lower oxygen affinity and increased 
proton leak when compared to men with equivalent maximal oxygen uptake (84). Furthermore, 
in animal models, it has been shown that female mitochondria produce less ROS and have higher 
oxidative capacity (81).   
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As for differences in redox signalling, it is known that female mitochondria have lower 
oxidative stress, lower oxidative stress biomarkers, produce less ROS, and have higher 
antioxidant potential than their male counterparts (81,85). Indeed, while female mitochondria are 
documented to have lower levels of GPX, they also have decreased ROS levels (85). It has been 
postulated that estrogen is the major factor for decreased ROS in female cells, due to the radical 
scavenging property of its phenolic hydroxy group (85). With this observation, it is implied that 
female mitochondria may be more efficient at maintaining ROS levels at optimal levels for redox 
signalling and preventing oxidative distress. This is supported by the fact that female 
mitochondria from brown adipose, white adipose, and skeletal muscle tissues show increased 
functionality compared to males (81). Additionally, rat brain tissue shows significantly lower 
oxidative damage in females than males (81). Furthermore, key signalling pathways of H2O2 
such as the NRF2, Mfn2, and Sirt1 have been shown to be decreased in female mice, indicating a 
sex dimorphism in redox regulation of these proteins and signalling pathways (81).  
1.7 Experimental Objectives and Hypotheses 
1.7.1 Objectives 
The primary objective of this project was to examine the metabolic response of female mice, 
on a C57BL/6N background, heterozygous for GRX2 (GRX2+/-) and WT littermates fed a high-
fat diet (HFD) compared to a control diet (CD). It was the goal of this research to ascertain the 
influence of a HFD on GRX2+/- mice in terms of: 
1) Weight gain, the mass of liver, muscle, kidney, heart, and subcutaneous adipose 
tissue, and circulating blood glucose and triglycerides.  
2) ROS production from different sites through the use of inhibitors and different carbon 
sources. 
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3) Mitochondrial respiration and proton leak. 
A secondary objective was evaluating if there was any sexual dimorphisms observed in 
this study in comparison to a previous study measuring the same parameters in male mice 
(59).  
1.7.2 Hypotheses  
 The broad hypothesis of this study was that female mice that are heterozygous for GRX2 
would gain lower adiposity then WT mice when placed on a HFD. More specifically, I 
hypothesized: 
1) Female GRX-/+ mice on a HFD will demonstrate resistance to diet-induced weight 
gain. 
2) Female GRX-/+ mice will generate more ROS than their WT littermates due to an 
increase in mitochondrial respiration (i.e., specifically phosphorylating and proton 
leak respiration). 
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2.1 Reagents 
ADP (20398-34-9-A2754), antimycin A (1397-94-0-A8674), ATP (34369-07-8-A1852), 
Bradford reagent (B6916), diethyl malonate (105-53-3), dimethyl sulfoxide (DMSO) (67-68-
5), ethylene glycol-bis (b-aminoethyl ether)-N,N,N’,N’- tetraacetic acid (EGTA) (13368-13-
3-E3889), fatty acid-free bovine serum albumin (BSA) (9048-46-8-A7030), HEPES sodium 
salt (75277-39-3-H7006), horseradish peroxidase (HRP) (9003-99-0-P8375), hydrogen 
peroxide (H2O2) (7722-84-1-216763), a-keto-beta-methyl-n-valeric acid (KMV) (24809-08-
3-74414), L-carnitine hydrochloride (6645-46-1-C0283), magnesium chloride (MgCl2) 
(7786-30-3-M8266), DL-malic acid (6915-15-7-240176), D-mannitol (69-65-8-M9647), 
monobasic potassium phosphate (7778-77-0-795488), myxothiazol (76706-55-3-T5580), 
oligomycin (579-13-5-75351), palmitoyl-carnitine chloride (18877-64-0-P1645), potassium 
chloride (KCl) (7447-40-7-P9333), REDExtract-N-Amp tissue PCR kit (XNATS), RIPA 
buffer (R0278), rotenone (83-79-4-R8875), sodium pyruvate (113-24-6-P2256), subtilisin A 
(9014-01-1-P5380), succinic acid (150-90-3-224731), sucrose (57-50-1-S7903), superoxide 
dismutase (SOD) (9054-89-1-S7571) were purchased from Sigma. Atpenin A5 (119509-24-
9) and CPI-613 (95809-78-2) were purchased from Santa Cruz. Ethanol (64-17-5), hydrogen 
chloride (HCl) (7647-01-0), nuclease-free water (AM9935), SYBR Safe Gel stain (A45205), 
Tris borate EDTA (TBE) (B52), and 100 bp DNA ladder (15628050) were purchased from 
Thermo Fisher Scientific. Amplex UltraRed (AUR) (A36006) and UltraPure Agarose 
(LS16500500) were purchased from Invitrogen. 96 well plates (655076) were purchased 
from Greiner Bio-One. DNA primer sequences were purchased from Integrated DNA 
Technologies.  
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2.2 Animals 
Female mice heterozygous for the glutaredoxin-2 gene (Grx2+/-) and wild type (WT) 
littermates were generated by breeding age-paired GRX2+/- mice housed in the animal care 
facility (~23 oC and 12 hour (h) dark/ 12 h light cycle, lights on at 0700 hours). The GRX2+/- 
mouse line were a generous gift from Dr. Mary-Ellen Harper (University of Ottawa) and 
generated from the C57BL/6N mouse strain as described in Wu et al. (86). Deletion of the gene 
encoding GRX2 was originally conducted by the S-Y Ho lab through the deletion of exon 2 of 
the gene leading to a truncated mRNA gene product more predisposed to degradation (86). This 
truncated mRNA still possesses exons 1,3, and 4 resulting in a protein product with a 
mitochondrial translocation sequence but only 8 out-of-frame amino acids from exon 3 (86). 
Previous work in our lab found that mice heterozygous for the Grx2 gene contain 50% less 
translational product compared to WT littermates (18). Additionally, total knockouts do not 
contain any GRX2 protein in the matrix of mitochondria (18). Breeding pairs were given free 
access to water and a standard chow diet (Teklad Global 18% protein rodent diet). New litters 
were weaned at three weeks of age and immediately ear notched for genotyping. Female WT and 
GRX2+/- littermates were fed a HFD (TD.06415) or matched CD (TD.06416) until 10 weeks of 
age (Table 2.1). Food and water consumption, body weight, and blood glucose measurements 
were taken weekly from week 4-10 weeks of age. 
Blood glucose measurements were conducted as follows. Mice were restrained and the 
vein in the hind leg was exposed. The area below the knee was sterilized with 75% ethanol and 
then a small amount of petroleum jelly was applied to allow the blood to bead up. Pressure was 
applied to the great saphenous vein to engorge veins in the lower leg and then an exposed vein 
was pricked with an A26 gauge ½ inch hypodermic needle. The beaded blood was collected on a 
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blood glucose test strip (FreeStyle) and glucose levels were measured using a FreeStyle Lite 
blood glucose monitoring system. Animals were cared for in accordance with the principles and 
guidelines of the Canadian Council on Animal Care and the Institute of Laboratory Animal 
Resources (National Research Council). All procedures using mice were approved by the Animal 
Care and Use Committee of Memorial University of Newfoundland. At 10 weeks of age, mice 
were anesthetized with isoflurane at which time blood was collected by cardiac puncture leading 
to exsanguination of the mice. The total amount of animals utilized was 45 mice.  
2.3 Genotyping 
2.3.1 DNA Extraction 
 DNA was extracted from ear notches collected from mice right after weaning (3 weeks of 
age) using the REDExtract-N-Amp Tissue PCR Kit (Sigma-Aldrich). Each ear notch was placed 
in separate 1.5 mL microcentrifuge tubes labeled with the animal identification number. One 
hundred microliters of extraction solution and 25 µL of tissue prep solution was added to each 
tube. Samples were then incubated at room temperature for 10 minutes, followed by an 
incubation at 95 oC for 5 minutes. Samples were then allowed to cool down and 100 µL of 
neutralization solution was added to each tube. All pipette tips and microcentrifuge tubes used 
during this preparation were certified nuclease-free. 
2.3.2 Polymerase chain reaction 
 Primers for Grx2 were obtained from Integrated DNA Technologies. Primer sequences 
were provided by Dr. Mary-Ellen Harper (University of Ottawa) and were generated based on a 
previously published study by Wu et al. (86). In an Eppendorf PCR tube, 16 µL of primer 
mixture (1 µL of 0.5 µM Grx2 forward primer, 1 µL of 0.5 µM Grx2 reverse primer, 1µL of 0.5  
µM Grx2 neo primer, 3 µL nuclease free water, and 10 µL REDExtract-N-Amp PCR ReadyMix;  
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Table 2.1: Macromolecule/ingredient breakdown of HFD and matched CD (Teklad) (87). 
Components TD.06415: High-Fat TD.06416: Control 
Fat 44.8% kcal (36 % 
saturated/47 % 
monounsaturated/17 % 
polyunsaturated) 
10.2% kcal (29 % 
saturated/37 % 
monounsaturated/34 % 
polyunsaturated) 
Protein 19% kcal 20% kcal 
Carbohydrate  36.2% kcal 69.8% kcal 
Formula (g/kg)   
Casein 245.0 210.0 
L-Cystine 3.5 3.0 
Corn Starch 85.0 280.0 
Maltodextrin 115.0 50.0 
Sucrose 200.0 325.0 
Lard 195.0 20.0 
Soybean Oil 30.0 20.0 
Cellulose 58.0 37.15 
Mineral Mix 43.0 35.0 
Calcium Phosphate, dibasic 3.4 2.0 
Vitamin Mix 19.0 15.0 
Choline Bitartrate 3.0 2.75 
Food colour 0.1 (Red) 0.1 (yellow) 
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Table 2.2) and 4 µL of extracted DNA solution was added. DNA sequences were then amplified 
using an Eppendorf EP Gradient Mastercycler PCR system (Table 2.3).  
2.3.3 Agarose gel electrophoresis 
 PCR samples were electrophoresed on a 1.5% (w/v) agarose gel which was made by 
dissolving 0.75 g of agarose powder (Fisher Scientific) in 0.5X Tris-Borate-EDTA (TBE, 10X 
solution diluted to 0.5X in analytical water) under heat. SYBR Safe DNA gel stain was added to 
the molten agarose (1/10,000 dilution), which was poured into a gel molding. The agarose was 
allowed to solidify and then set up in a Fisher Biotech Horizontal Electrophoresis System gel 
box. Five microliters of Trackit 100 base pair (bp) DNA Ladder (Fisher Scientific) was loaded 
into the first well to estimate DNA fragment size and 10 µL of the PCR products was loaded into 
the wells. Samples were electrophoresed for 40 minutes at 90 volts and nucleotide sequences 
corresponding to the amplified Grx2 gene were visualized with an Alpha Innotech ChemiImager 
Ready System. WT mice produced a single nucleotide sequence that was 729 bp in size, Grx2 -/- 
mice produced a fragment 510 bp in size, and Grx +/- mice contained both nucleotide fragments 
(Figure 2.1). 
2.4 Buffer Preparation  
2.4.1 Basic Medium  
 Basic medium (BM) was utilized for all experiments involving skeletal muscle. The 
medium was made fresh on a routine basis and stored at 4 oC for up to a month. BM consists of 
HEPES (20 mM) to buffer the solution, EGTA (1 mM) as a chelating agent to bind Ca2+ ions, 
MgCl2 (5 mM) to stabilize ADP for phosphorylation, and KCl (140 mM) as an osmolyte. The pH 
of the buffer was adjusted to 7.0 using 2 M HCl.  
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Table 2.2: Primer sequences for amplification of Grx2 gene. 
Forward 5’-GAC CTA GCC TAC CAG ACT TGG 
CTG AAA TTT ATT C-3’ 
Reverse   5’-CAT AGA CAC TCT TCA CTT TCA 
AGC CCA CCC TC-3’ 
Neo 5’- CCT ACA TTT TGA ATG GAA GGA 
TTG GAG CTA CGG G-3’ 
 
Table 2.3: PCR protocol for amplification of Grx2 gene.  
Step 1 94 oC for 5 minutes 
Step 2 (x30) 94 oC for 30 seconds, 63 oC for 1 minute, 72 
oC for 1 minute 
Step 3 72 oC for 7 minutes  
 
 
 
 
 
 
 52 
 
 
 
 
Figure 2.1: Agarose gel electrophoresis of PCR products to identify mouse genotype.  
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2.4.2 Homogenizing Medium 
Muscle mitochondria were isolated in homogenizing medium (HM). The medium was 
made fresh on the day of experiments and kept on ice. HM consisted of BM containing 1 mM of 
ATP to promote myofiber depolymerization and the release of intramyofibrillar mitochondria, 
1% (w/v) fatty acid free BSA to remove contaminating fatty acids and prevent the uncoupling of 
mitochondria, and 1 U subtilisin A, a protease required to digest myofibers. The amount of 
subtilisin A for muscle tissue homogenization was determined by the following: 
 
Equation 2.1: 
𝑿	𝒖𝑳	𝒐𝒇 𝟏𝒎𝒈𝒎𝑳 𝒔𝒖𝒃𝒕𝒊𝒍𝒊𝒔𝒊𝒏	𝑨	𝒔𝒐𝒍𝒖𝒕𝒊𝒐𝒏 = 𝒎𝒖𝒔𝒄𝒍𝒆	𝒘𝒆𝒊𝒈𝒉𝒕𝟏𝒎𝒈𝒎𝑳 𝒙	𝟏𝟏. 𝟕	𝒎𝒈/𝒖𝒏𝒊𝒕 
 
2.4.3 Mannitol/EGTA/Sucrose/HEPES buffer 
 Mannitol/EGTA/sucrose/HEPES buffer (MESH) was utilized for all substrates and 
reagents pertaining to experiments with liver mitochondria. The medium was made fresh on a 
routine basis and stored at 4 oC for up to a month. MESH buffer consisted of 220 mM mannitol 
to quench hydroxyl radicals, 1 mM EGTA to chelate calcium ions, 70 mM sucrose to maintain 
osmolality, and 20 mM HEPES to buffer the solution. The pH was brought to 7.4 with 2 M HCl. 
MESH-B was utilized during mitochondrial isolation procedures and consisted of MESH and 
0.5% (w/v) fatty acid-free BSA to remove contaminating fatty acids.   
2.4.4 Respiration Medium  
 Respiration buffer was used for the polarographic measurement of oxygen consumption. 
For muscle mitochondria this medium consisted of basic medium supplemented with 10 mM 
 54 
KH2PO4, to provide phosphate ions for ATP production and 0.5% (w/v) BSA to remove 
contaminating fatty acids. For liver mitochondria, this medium consisted of MESH-B 
supplemented with 10 mM KH2PO4 and 2 mM MgCl2.   
2.5 Histological Analysis 
 Haematoxylin and Eosin (H & E) and Periodic Acid-Schiff (PAS) staining was 
performed on isolated liver and muscle tissue and Oil Red O staining was performed exclusively 
on liver tissue. These were used for qualitative analysis of cell morphology, glycogen stores, and 
lipid accumulation respectively. Both were completed by the histology unit of the Medical 
Education and Laboratory Support Services at Memorial University’s Faculty of Medicine. 
Tissue for H & E and PAS staining was prepared by emersion in 4% formalin upon isolation and 
Oil Red O liver sections were prepared by flash freezing in liquid nitrogen. Images were taken 
with an upright biological microscope equipped with a SPOT RT CCD Cool camera under bright 
field conditions.  
2.6 Serum Biochemistry  
Mice were heavily anesthetized with isoflurane at which time blood was collected by cardiac 
puncture leading to exsanguination of the mice. Cardiac puncture was performed with a 
heparinized (10,000 USP units/10 mL) 1 mL syringe with a 26-gauge, 1/2-inch needle. Once the 
mouse was heavily anesthetized a transverse incision was made exposing the mouse diaphragm 
and giving direct access to the heart. The needle was pushed through the diaphragm and into one 
of the heart ventricles and whole blood extracted until exsanguination. Whole blood was then 
transferred from the syringe into a 1.5 mL microcentrifuge tube on ice. Once remaining tissues 
were excised, whole blood was centrifuged at 2000 xg for 5 minutes to separate blood serum. 
Blood serum was decanted and placed in a separate 1.5 mL microcentrifuge tube and stored at     
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-80 oC. Prior to each assay, frozen blood serum was removed from -80 oC storage and allowed to 
thaw on ice.  
2.6.1 Triglyceride levels 
The L-type Triglyceride M assay kit from Wako Pure Chemical industries was utilized 
for determinations of serum triglyceride levels (Figure 2.2). Assays were conducted according to 
the manufacturer’s instructions. A 5-point calibration curve was generated using the Wako 
Multi-Calibrator Lipids by addition of 4, 8, 12, and 16 µL of the calibrator lipid solution to 
separate wells in duplicate, corresponding to triglyceride concentrations of 100 mg/dL, 200 
mg/dL, 300 mg/dL, and 400 mg/dL, respectively. Four microliters of analytical water (as a 
blank) and the unknown samples were also added to separate wells in duplicate. Ninety 
microliters of the R1 (colour A) solution were added to each well and mixed by gentle rotation at 
37 ºC for 10 minutes. This solution contains the following: 
• 50 U/mL glycerol kinase (GK) 
• 8.0 mM ATP 
• 5.6 U/mL Glycerol-3-phosphate oxidase (GPO) 
• 150 U/mL Catalase 
• 0.4 mM N-(3-isopropyl)-3methoxy-5-methylaniline (HMMPS) 
• 2.0 U/mL ascorbate oxidase  
The absorbance was measured at 600 nM using a SpectraMax M5 plate reader. This 
reading is established as the sample blank. Following this 30 µL of R2 (colour B) solution was 
added to each well and mixed by gentle rotation at 37 ºC for 10 minutes. This solution contains 
the following: 
• 250 U/mL lipoprotein lipase (LPL) 
• 25 U/mL horseradish peroxidase (HRP) 
• 4.6 mM 4-aminoantipyrine 
 56 
The absorbance is again read at 600 nm using a SpectraMax M5 plate reader. The final 
absorbance was calculated as the difference between the two absorbances and a standard curve 
generated to determine that concentration of triglycerides in the unknown samples. 
2.6.2 Glutathione/ Glutathione Disulfide Pool 
The glutathione assay kit from Sigma Aldrich was used to assess serum GSH and GSSG 
concentrations (Figure 2.3). Assays were conducted according to manufacturer’s instructions. A 
5-point standard curve was generated with the following nmoles GSH: 0.0312, 0.0625, 0.125, 
0.25, 0.5. Twenty-five microliters of each serum sample were transferred to a new Eppendorf 
tube. Two hundred microliters of 5% 5-sulfosalicylic acid were added to each tube to 
deproteinize the sample. The samples were then vortexed vigorously and incubated at 4 ºC for 10 
minutes followed by centrifugation at 10,000 x g for 10 minutes. Samples and standards 
provided in the kit were loaded into individual wells of a 96 well plate in duplicate. One hundred 
and fifty microliters of working mix (pH 7.0) containing potassium phosphate buffer (95 mM), 
EDTA (0.95 mM), 5,5’-dithiobis (2-nitrobenzoic acid) (DTNB; 0.031 mg/mL), glutathione 
reductase (0.115 U/mL), was added to each well and incubated for 5 minutes with agitation. Fifty 
microliters of the NADPH solution (0.038 mg/mL) was added to each well and the absorbance 
was read with a kinetic read at 412 nm at 1 minute intervals for 5 minutes using a SpectraMax 
M5 plate reader. The GSH standards were utilized to generate a standard curve. The GSH 
concentration in the unknown samples were interpolated from the standard curve.  
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Figure 2.2: Principle of L-type Triglyceride Assay. (A) Glycerol kinase utilizes ATP to 
convert free glycerol to glycerol-3-phosphate which is subsequently converted to 
dihydroxyacetone phosphate coupled with the generation of H2O2 by the action of glycerol-3-
phosphate oxidase. The H2O2 generated is neutralized to H2O by the action of catalase. (B) 
Lipoprotein lipase cleaves triglycerides generating free fatty acids and glycerol. Glycerol is once 
again converted to dihydroxyacetone phosphate by glycerol kinase and glycerol-3-phosphate 
oxidase at the expense of ATP and coupled with the generation of H2O2. HMMPS and 4-
aminoantipyrine undergo condensation to form a blue pigment in the presence of HRP and H2O2. 
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2.6.3 Protein Carbonyl Content Assay 
 The protein carbonyl content assay kit from Abcam was utilized to quantify protein 
carbonyls in mitochondrial samples. Protein carbonyl groups can be a biomarker for oxidative 
stress and the assay works by the derivatization of protein carbonyl groups with 2,4-
dinitrophenylhydrazine (DNPH) leading to the formation of stable dinitrophenyl (DNP) 
hydrazine adducts that can be detected spectrophotometrically. Assays were conducted according 
to manufacturer’s instructions. Mitochondrial samples for liver and muscle were diluted to 3 
mg/mL in 100 µL of RIPA buffer in a 1.5 mL microcentrifuge tube. To remove nucleic acids that 
can interfere with the assay, 10 µL of Streptozocin was added to each sample, incubated for 15 
minutes at room temperature, and centrifuged at 13,000 x g for 5 minutes. Supernatant from the 
previous step was placed in new tube and 100 µL of DNPH was added to each sample, vortexed, 
and incubated at room temperature for 5 minutes. Then 30 µL of 100% TCA was added, 
vortexed, and placed on ice for 5 minutes. Samples were then centrifuged at 13,000 x g for 2 
minutes and supernatant removed. Pellets from previous step were washed twice by resuspension 
in 500 µL of cold acetone, vortexed for 30 seconds, incubated at -20 oC for 5 minutes, and then 
centrifuged at 13,000 x g for 2 minutes. Washed pellets were resolubilized in 200 µL of 6 M 
guanidine solution and 100 µL of each sample and a 100 µL H2O blank were loaded into a 96  
well plate in duplicate. The absorbance was read at 375 nm using a SpectraMax M5 plate reader 
and amount of carbonyl per well per mg protein was determined by: 
 
Equation 2.2:  
𝑪 = 𝑨𝟑𝟕𝟐 − 𝑩𝒍𝒂𝒏𝒌𝟔. 𝟑𝟔𝟒 𝒙𝟏𝟎𝟎𝟎. 𝟑  
6.364 = millimolar extinction coefficient (22 mM-1cm-1) times path length (0.2893 cm) 
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Figure 2.3: The GSH in this assay acts as a catalyst for the continuous reduction of 
DNTB to 5-thio-2-nitrobenzoic acid (TNB), a yellow substance. The GSSG formed is recycled 
by glutathione reductase and NADPH (GSSG present will also react to produce a positive value). 
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100 = total volume in well 
0.3 = mg protein in well 
2.7 Skeletal Muscle and Liver Mitochondria Isolation 
 All steps for tissue dissection and the isolation of mitochondria were carried out on ice or 
at 4 oC. At 10 weeks of age, mice were anesthetized with isoflurane and euthanized by cardiac 
puncture. Mice were then dissected and forelimb, hindlimb, and pectoral muscles were pooled in 
ice-cold BM while other organs were placed in MESH. All tissues were weighed and then pooled 
muscle and liver were placed in buffer. For the isolation of muscle mitochondria, connective 
tissue and fat were removed from the pooled samples, and then the tissue was dried and weighed 
to measure total tissue mass. Pooled muscles were minced on a Teflon watch glass using a steel 
razor. The minced tissue was then placed in 30 mL of homogenizing buffer. Tissue 
homogenization was carried out with a Glas-Col variable speed automatic tissue homogenizer 
(Cole-Palmer) for muscle. The tissue was completely homogeneous after ~6 to 10 passes with 
the Teflon pestle. Muscle homogenates were then centrifuged at 800 x g for 9 minutes. The 
supernatants were then collected and centrifuged at 12,000 x g for 9 minutes. The liquid was 
decanted, and the remaining pellet was resuspended in 1 mL of BM and incubated on ice for 5 
minutes. Incubation of the resulting muscle pellet in BM promotes the repolymerization of any 
remaining myofibers allowing for their easy removal by low-speed centrifugation. After the 
incubation, 26 mL BM was added to each tube and the samples were centrifuged at 800 x g for 9 
minutes to remove repolymerized myofibers. The supernatant was collected and then centrifuged 
at 12,000 x g for 9 minutes. The final mitochondria pellet was then resuspended in 200 µL of 
BM for muscle. 
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For liver mitochondria, tissues were minced on a Teflon watch glass and then 
homogenized using the Potter Elvejham method (~20 passes). The homogenate was then 
centrifuged at 800 x g for 9 minutes to pellet undisrupted material. The supernatant was collected 
and then centrifuged at 12,000 x g for 9 minutes. The solution was decanted and the sides of the 
centrifuge were carefully cleaned with a Kimwipe to remove excess fat. The pellet was 
suspended in 1 mL of MESH-B and then topped up to 26 mL with MESH-B and centrifuged at 
12,000 x g for 9 minutes. The solution was decanted and the pellet was resuspended in 500 µL 
MESH. All centrifugations were performed with a Thermo Sorvall RC6+ centrifuge. 
Mitochondria were then stored on ice and used immediately for assays. Any remaining 
mitochondria were stored at -80 oC for later use. 
2.8 Bradford Assay 
2.8.1 Protein concentration 
Protein equivalents to mitochondria was determined using the Bradford assay. This assay 
works under the principle that protein molecules (namely basic amino acids residues) bind to 
Coomassie dye under acidic conditions resulting in a pigment change of brown to blue. One 
microliter of mitochondria was diluted in 999 µL of analytical grade water. Samples were then 
vortexed vigorously and 50 µL of the diluted mitochondria was added to 200 µL of Bradford 
reagent. Then 750 µL of analytical water was added and the mixture vortexed vigorously. Two 
hundred microliters of the Bradford mixture was loaded into a black 96 well plate in duplicate 
and the absorbance was read at 595 nm using a SpectraMax M5e plate reader (Molecular 
Devices) and Softmax pro software (version 5.4.6). Protein concentration equivalent to 
mitochondria was then calculated using a standard curve.  
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2.8.2 Standard Curve 
The standard curve was constructed by mixing increasing concentrations of BSA (0-
1.875 µg/mL) with Bradford reagent and diluting with analytical water, precisely as described 
above. Changes in absorbance were then measured and values plotted on the y-axis while the 
corresponding concentrations plotted on the x-axis (Figure 2.4). This allowed unknown protein 
concentrations to be determined from their absorbance. The final concentration of proteins 
equivalent to mitochondria was ~7-20 mg/mL for muscle and ~15-40 mg/mL for liver. 
2.9 Amplex UltraRed Assay 
 The Amplex UltraRed (AUR) assay was used to quantify the rate of O2•- / H2O2 
production by isolated mitochondria. AUR is a non-fluorescent molecule which reacts with H2O2 
in the presence of horseradish peroxidase (HRP) to form fluorescent resorufin, as depicted in 
Figure 2.5. For these assays, mitochondria were first diluted to 1.5 mg/mL (skeletal muscle) in 
BM or 3.0 mg/mL (liver) in MESH, respectively. Samples were then diluted to 0.15 mg/mL or 
0.3 mg/mL, respectively, in the wells of a black 96 well plate. Mitochondria were then incubated 
for 5 minutes at 25 oC. Fifty micromolar carnitine was included in the incubation medium for 
experiments using palmitoyl-carnitine. Wells were then incubated for 10 minutes at 25 oC either 
in the presence or absence of various site specific O2•- / H2O2 inhibitors (Figure 2.5). The 
inhibitors served as a negative control to ensure that changes in resorufin fluorescence was 
associated with the detection of H2O2 by mitochondria and not due to non-specific auto-
oxidation. Additionally, inhibitors were chosen based on the substrate that was being oxidized 
during our measurements and concentrations based on previous literature (19,52). The inhibitors 
used were as follows; CPI-613 (150 µM; Pyruvate/Liver), KMV/Rotenone (10 mM/4 µM; 
Pyruvate/Muscle), Malonate (5 mM; Succinate), Roteone/Mxothiazol/Aptein A5 (4 µM/4 µM/40  
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Figure 2.4: BSA standard curve for which the equation of the line of best fit was utilized to 
determine mitochondria protein concentration. 
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µM; Palmitoyl-carnitine)(Figure 2.5). After the incubation, SOD (25 U/mL), HRP (3 U/mL), and 
AUR (10 µM) were added to the samples and the reaction initiated by the addition of substrate 
(50 µM Pyruvate/50 µM Succinate/50 µM palmitoyl-carnitine). 
For this assay the concentration of AUR is kept low at 10 µM due to the ability of AUR 
to inhibit mitochondrial respiration at higher concentrations. For the concentration of substrates 
chosen, these substrate concentrations represent physiological levels that produce maximal O2•-/ 
H2O2 (88). Furthermore, exogenous addition of SOD preserves the accuracy of O2•-/ H2O2 
measurement by limiting peroxynitrite formation by O2•-, which has the capacity to react with 
AUR (89). Additionally, the reaction of HRP and H2O2 forms a compound (Compound I) 
responsible for the equimolar formation of resorufin, compound I reacts with fluxes of O2•- (89). 
Dual wavelength fluorescence changes were then measured over 5 minutes at 30 second intervals 
using a Spectramax M5 plate reader set to an excitation/emission 565 nm:600 nm (AUR) and 
376 nm:450 nm (NAD(P)H). Values of resorufin fluorescence were converted into O2•-/ H2O2 
produced using a H2O2 standard curve, generated from using 0, 20, 50, 200, 500, and 1000 nM 
H2O2 stock solution. To determine rate of O2•-/ H2O2 production the following equation was used 
to get a rate as per min/mg protein: 
 
Equation 2.3: 𝑭𝒊𝒏𝒂𝒍	𝑪𝒐𝒏𝒄𝒆𝒏𝒕𝒓𝒂𝒕𝒊𝒐𝒏 − 𝑰𝒏𝒊𝒕𝒂𝒍	𝑪𝒐𝒏𝒄𝒆𝒏𝒕𝒓𝒂𝒕𝒊𝒐𝒏𝟓	𝒎𝒊𝒏𝒖𝒕𝒆𝒔÷𝒎𝒊𝒕𝒐𝒄𝒉𝒐𝒏𝒅𝒊𝒂𝒍	𝒄𝒐𝒏𝒄𝒆𝒏𝒕𝒓𝒂𝒕𝒊𝒐𝒏	𝒊𝒏	𝒘𝒆𝒍𝒍 
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Figure 2.5: (A) Depiction of Amplex UltraRed reaction with horseradish peroxidase and 
hydrogen peroxide. Superoxide dismutase (SOD) supplementation ensures any superoxide 
present is converted to hydrogen peroxide. (B) Site-specific inhibition of O2•-/ H2O2 for the 
chemicals used as controls for Amplex UltraRed Assay. 
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2.10 Polarographic Measurement of Mitochondrial Respiration 
 The mitochondrial health index can be measured by monitoring the different states of 
respiration. This was achieved using an Oxytherm electrode system (Hansatech) (Figure 2.6). 
The Oxytherm chamber measures the partial pressure of O2 using a platinum anode and silver 
cathode that are separated by a KCl solution. Molecular oxygen from the chamber diffuses 
through the PVDF membrane, making contact with the silver cathode where it is reduced 
forming H2O2. The resulting H2O2 is then oxidized by the platinum anode creating a current that 
is proportional to the partial pressure of O2 in the chamber. Therefore, the rate of O2 
consumption measured by a population of mitochondria is inversely proportional to the 
amperage traveling through the anode. Mitochondrial were diluted to 0.2 mg/mL (muscle) or 0.5 
mg/mL (liver) in the reaction chamber containing respiration medium. State 2 respiration was 
then induced by the addition of substrates malate (2 mM)/pyruvate (10 mM) or succinate (5 
mM). State 2 respiration was induced once a stable O2 baseline level was reached, mitochondria 
respired under these conditions for a few minutes to establish a PMF. This was followed by the 
addition of ADP (1 mM) to induce state 3 (phosphorylating respiration). This effectively 
completes the respiratory chain by allowing proton return from the intermembrane space into the 
mitochondrial matrix through complex V, driving up respiration. Once ADP was completely 
exhausted from the reaction chamber, oligomycin (4 µg/mL) was added to the reaction chamber 
to measure state 4 respiration (proton leak-dependent respiration associated with the return of 
protons to the matrix using complex V-independent systems). Oligomycin serves as a complex V 
inhibitor but also prevents the metabolism of ATP back to ADP by any contaminating ATPases. 
Therefore, addition of oligomycin ensures that respiration associated with leaks is accurately  
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Figure 2.6: Trace of oxygen concentration during the different states of respiration in an 
Oxytherm Clark-type electrode.  
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measured. Final volume in the reaction chamber was 1 mL and reactions were halted by the 
addition of antimycin A (4 µM), a complex III inhibitor. Respiratory control ratio (RCR) values 
were calculated as the state 3 to state 4 respiration and is a proxy measure of the ATP producing 
potential of mitochondria.  
2.11 Data Analysis 
 Graphpad Prism 6 software was utilized for all statistical analysis. Data are represented 
either as the mean ± standard error of the mean (SEM) or mean ± standard deviation (SD) with n 
³ 4. Two-way ANOVA repeated measures was utilized to determine significance when 
comparing repeated measures over time. Two-way ANOVA with a Tukey’s post-hoc test was 
utilized to determine significance when comparing two variables between groups. Statistical 
significance was represented as the following: 
*/#              P £ 0.05 
**/##              P £ 0.01 
***/###  P £ 0.001 
****/####  P £ 0.0001 
 
 
 
 
 
  
 69 
 
 
 
 
 
 
 
 
 
Chapter 3: Results 
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3.1 Deleting the Grx2 gene does not alter the response of mice towards high-fat feeding. 
3.1.1 Deleting the Grx2 gene does not alter the weight gain profile of mice fed a HFD. 
 Our group observed previously that the male C57BL/6N mice containing a deletion for 
the gene encoding GRX2 did not display any alterations in weight gain, adipose tissue mass, or 
circulating insulin and triglyceride levels and were protected from intrahepatic lipid 
accumulation and preserved liver glycogen levels (59). This was in contrast to male WT 
littermates where high-fat feeding induced weight gain, insulin resistance, and fatty liver disease 
(59). In the present thesis, we conducted a similar study except on female mice containing a 
deletion for Grx2. To examine the role that GRX2 protein plays in female metabolism, a whole 
body Grx2 deficient mouse model was generated from a heterozygous GRX2 breeding pair.  
 From 3 to 10 weeks of age, there was no diet or genotypic differences in mouse weight-
gain profiles (Figure 3.1A). Indeed, it was observed that Grx2 +/- mice on CD and HFD had the 
same weight-gain trend as WT littermates on both diets. This observation was independent of 
food and water consumed over the 7-week diet (Figure 3.1B-C). These data are in contrast to the 
male study in which it was observed that WT mice on a HFD gained significantly more mass 
than the WT mice on matched CD (59). Indeed, male WT mice had a significant increase in 
weight gain as early as 4 weeks when fed a HFD in the WT, while Grx2 +/- mice displayed a 
weight gain profile that was identical to the control group (59). Additionally, male WT mice fed 
a HFD also displayed a significant increase in circulating triglycerides and insulin, an effect that 
was not observed in the male Grx2+/- littermates (59). Here, however, I observed no statistically 
significant changes in circulating glucose (Figure 3.2A) or triglycerides (Figure 3.2B) in female 
mice fed either CD or HFD. Furthermore, no genotype effect was observed in WT and Grx2 +/- 
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mice fed a HFD. It should be noted here that the CD and HFD used in the female study were 
identical to those in the male study.  
At ~10 weeks of age, mice were euthanized and subcutaneous abdominal fat pads were 
excised and weighed as a proxy for mouse obesity. Compatible with mouse body weight data 
there was no significant difference in mouse adipose tissue mass between groups (Figure 3.3A). 
This result contrasts with male mice where a significant increase in the mass of the abdominal fat 
pad was observed in the WT mice on a HFD, an effect that was absent from Grx2+/- littermates 
(59). This contrast shows a distinct resistance to DIO in WT female mice that is absent in male 
mice. Furthermore, these findings indicate that deleting the gene encoding GRX2 does not have 
the same metabolic effects on female mice as observed in the male counterparts. Organ weights 
were also not significantly different for muscle, kidney, and heart in female mice between 
genotype or diet (Figure 3.3B-D). However, there was a significant diet effect on liver mass in 
both the WT and Grx2 +/- female mice fed an HFD. Indeed, liver mass was significantly lower in 
mice fed a HFD when compared to the control groups (Figure 3.3E). Additionally, there was a 
significant difference between WT and Grx2 +/- mice on HFD, with WT mice displaying 
increased liver mass (Figure 3.3A).  
3.1.2 Increased Liver Fat Deposition and Increased Glycogen Storage 
 Next, we conducted histological analyses on liver and muscle tissue to determine if diet 
and genotype affected the overall morphology of hepatocytes or differentiated polynucleated 
muscle fibers. H & E staining of hepatocytes determined that there was no observable difference 
in the overall morphology of these cells (Figure 3.4). Similar observations were made with 
muscles – there was no diet or genotype effect on the overall morphology of the muscle fibers 
(Figure 3.4). Oil Red O staining was also performed on hepatocytes to determine if there was any 
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difference in intrahepatic lipid accumulation in mice fed both diets. There appeared to be an 
increase in the size of lipid droplet stains in WT/HFD mice and to a smaller extent Grx2 +/-/CD 
mice when compared to WT/CD mice (Figure 3.5). There also appeared to be an increase in lipid 
staining in liver sections from the Grx2 +/- mice fed a HFD, but this staining does not appear to 
correlate to increased size of lipid droplets but instead an increase in abundance of droplets 
(Figure 3.5). 
 Intrahepatic glycogen content was evaluated using a Periodic Acid-Schiff (PAS) stain. 
Stains were conducted on samples treated with amylase as a control, a glycoside hydrolase that 
degrades polysaccharides into their corresponding monosaccharide units. PAS non-specifically 
stains polysaccharides, including cell surface polysaccharides on glycoproteins. Therefore, 
treating samples with amylase is an important control since it allows one to discern how much of 
the overall stain is associated with glycogen granules housed in the intrahepatic environment. 
This staining revealed that glycogen appears to have increased deposits in the WT mice on an 
HFD when compared to the other three groups (Figure 3.6). It also appears that there is more 
glycogen storage in Grx2 +/- mice compared to the WT/CD mice (Figure 3.6). The results from 
Oil Red O and PAS staining appears to reveal that the difference in liver masses observed was 
due to differences in lipid accumulation and glycogen storage in hepatocytes. However, it is not 
possible to determine whether it is lipid or glycogen storage that is the dominant factor.   
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Figure 3.1: Mouse measurements taken from 3 to 10 weeks of age (A) Mouse mass (B) Food 
consumption (C) Water consumption. n = 4-8, mean ± SD, two-way repeated measures ANOVA. 
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Figure 3.2: (A) Non-fasted mouse blood glucose levels taken ~18:00 h weekly from 4 to 10 
weeks. WT (n = 4), GRX2+/- (n=5); mean ± SD, two-way repeated measures ANOVA.  
 (B) Mouse triglyceride levels in blood serum collected by cardiac puncture on non-fasted mice, 
n = 4, mean ± SEM, two-way ANOVA.  
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Figure 3.3: Mouse organ mass corrected to mouse body mass (A) Adipose tissue (B) Muscle (C) 
Kidney (D) Heart (E) Liver. WT(CD) n = 6, WT(HFD) n = 7, GRX2+/-(CD) n = 9, GRX2+/-
(HFD) n = 9; mean ± SD, two-way ANOVA with Tukey’s post-hoc test. * represents genotypic 
differences while # represents differences between diet.  
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 Figure 3.4: Hematoxylin and Eosin staining of liver (top) or gastrocnemius muscle (bottom) 
sections prepared from 10 week old Grx2+/- mice and littermates fed a CD or HFD, to determine 
if diet or genotype had effect on overall morphology (n = 3). 
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Figure 3.5: Oil Red O staining of liver sections prepared from 10 week old Grx2+/- mice and 
littermates fed a CD or HFD, to determine differences in intrahepatic lipid accumulation, lipid 
droplets represented as red staining (n = 3). 
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Figure 3.6: Periodic acid-Schiff stain of liver sections prepared from 10 week old Grx2+/- mice 
and littermates fed a CD or HFD, purple stain represents staining of polysaccharides, mucus 
substances, and basement membranes. (A) Amylase positive slides, which digests carbohydrates 
and represents glycogen absent staining. (B) Amylase-negative slides, represents total staining (n 
= 3).  
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3.2 Impact of Deleting Grx2 Gene on O2•-/H2O2 Production 
3.2.1 Liver Mitochondria ROS Production 
 The rate of O2•-/H2O2 release by mitochondria energized with pyruvate/malate revealed a 
genotype difference in production between WT and Grx2+/- littermates fed a HFD (Figure 3.7A). 
Indeed, when challenged with a HFD, Grx2+/- mice had elevated levels of O2•-/ H2O2 compared 
to WT littermates fed the same diet. However, I observed no statistically significant diet-
dependent effects for liver mitochondria isolated from WT and Grx2+/- mice (Figure 3.7A). 
Reaction chambers were also supplemented with CPI-613, a keto acid dehydrogenase inhibitor, 
to confirm that the change in resorufin fluorescence was associated with ROS produced by 
mitochondria oxidizing pyruvate. CPI-613 is a lipoic acid analog and thus inhibits keto acid 
dehydrogenase activity by forming covalent adducts with the vicinal protein thiols in the E2 
subunit of the enzyme complex. This curtails substrate oxidation and the transfer of electrons 
from lipoic acid in the E2 subunit to the FAD center in the E3 subunit, which happens to be the 
source of ROS in keto acid dehydrogenases like PDH or KGDH (52). Treatment with the 
inhibitor induced a significant decrease in O2•-/H2O2 production by liver mitochondria isolated 
from WT and Grx2+/- mice fed either diet, confirming that changes in resorufin fluorescence 
were due to mitochondrial ROS production (Figure 3.7A). When liver mitochondria were 
supplemented with succinate or palmitoyl-carnitine there was no genotypic or diet differences 
observed (Figure 3.7B-C). Malonate, which competes for the succinate binding site in complex 
II, was used as a control when succinate served as the electron donor. Inclusion of malonate 
induced a significant decrease in O2•-/H2O2 production (Figure 3.7B). For palmitoyl-carnitine 
driven ROS production, a combination of rotenone, myxothiazol, and atpenin A5 was added as 
the control. Unlike the other controls, addition of this combination of inhibitors significantly 
 80 
elevated O2•-/H2O2 production (Figure 3.7C). This is an expected outcome since these inhibitors 
block complex I, II, and III causing increased reduction of ETFQO and long chain fatty acid 
dehydrogenase, enzymes required for fatty acid oxidation which happen to serve as ROS sources 
(90).  
3.2.2 Muscle Mitochondria ROS Production 
 O2•-/H2O2 production by muscle mitochondria was profiled with no significant 
differences with pyruvate/malate, succinate, or palmitoyl-carnitine oxidation (Figure 3.8). The 
same controls as liver were used except for pyruvate/malate. While inhibition with CPI-613 was 
attempted in this case, it was not successful at reducing O2•-/H2O2 emission (data not shown). To 
correct this, the concentration of CPI-613 was doubled (300 µM) which was also unsuccessful at 
reducing ROS production (data not shown). Due to this lack of effect, we next attempted to 
inhibit ROS production using KGDH inhibitor, KMV and rotenone, a complex I inhibitor. 
Surprisingly, a combination of KMV and rotenone did not elicit an effect either (Figure 3.8A). 
Additionally, including KMV and rotenone induced a trend (P=0.1699) for an increase in ROS 
production, although this was not significant. PDH has been shown to be a potent ROS producer 
in muscle mitochondria from mouse, rat, and human myofibers (14,91,92). Thus, it is possible 
that these inhibitor combinations were not effective simply because PDH is a highly effective 
ROS generator in muscle tissue. The use of malonate during succinate oxidation showed 
significant reduction in O2•-/H2O2 production (Figure 3.8B). Addition of an inhibitor cocktail 
comprised of rotenone, atpenin A5, and myxothiazol to muscle mitochondria oxidizing 
palmitoyl-carnitine abolished O2•-/H2O2 emission (Figure 3.8C). This is not surprising since the 
main ROS sources in muscle mitochondria oxidizing palmitoyl-carnitine are complexes I, II, and 
III, with ETFQO making a negligible contribution (13).      
 81 
 
Figure 3.7: Rates of O2•-/H2O2 production by liver mitochondria supplemented with (A) 
Pyruvate (50 µM)/malate (50 µM) (B) Succinate (50 µM) (C) Carnitine (50 µM)/palmitoyl-
carnitine (50 µM). Mitochondria were diluted to 0.3 mg/mL in reaction wells with or without 
inhibitors (A) CPI-613 (150 µM) (B) Malonate (5 mM) (C) Rotenone (4 µM)/myxothiazol (4 
µM)/aptenin A5 (40 µM) and changes in ROS production were then measured. n = 4, mean ± 
SEM, two-way ANOVA with Tukey’s post-hoc test. * represents genotypic difference while # 
represents difference between diets.  
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Figure 3.8: Rates of O2•-/H2O2 production by muscle mitochondria supplemented with (A) 
Pyruvate (50 µM)/malate (50 µM) (B) Succinate (50 µM) (C) Carnitine (50 µM)/palmitoyl-
carnitine (50 µM). Mitochondria were diluted to 0.15 mg/mL in reaction wells with or without 
(A) Rotenone (4 µM)/KMV (10 mM) (B) Malonate (5 mM) (C) Rotenone (4 µM)/myxothiazol 
(4 µM)/aptenin A5 (40 µM) and changes in ROS production were then measured. n = 4, mean ± 
SEM, two-way ANOVA with Tukey’s post-hoc test. # represents difference between diets.  
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3.3 High-fat Diet and Grx2 Deficiency Decreases Protein Oxidation Without Impacting 
Total Glutathione Levels 
Since liver mitochondrial O2•-/H2O2 profiling revealed a genotypic difference in ROS 
production when oxidizing pyruvate, a protein carbonyl assay was performed to determine if 
there was any alteration in the redox state of the mitochondrial environment. A protein carbonyl 
assay is a simple and accurate way to quantify carbonyl groups, biomarkers for oxidative stress. 
Quantification of protein carbonyl content of liver mitochondria revealed that there was a 
significant decrease in WT/HFD mice along with Grx2+/- mice on both diets, compared to the 
WT/CD mice (Figure 3.9A). Quantification of protein carbonyls in muscle mitochondria 
revealed no significant diet or genotypic differences (Figure 3.9B). 
Next, we assessed total circulating glutathione and the redox state of the glutathione pool 
in the blood stream to determine if diet and genotype affected redox buffering capacity. It can be 
seen in figure 3.9C that there is no significant difference in total amount of glutathione in the 
blood serum, suggesting that there is no change in glutathione biosynthesis or degradation. 
However, calculation of the reduction potential of the pool, represented as the ratio of reduced to 
oxidized glutathione, revealed that challenging mice from either genotype with an HFD led to a 
significant oxidation of circulating glutathione (Figure 3.9D).  
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Figure 3.9: Protein carbonyl content in (A) Liver mitochondria (B) Muscle mitochondria. 
Amount of (C) Total glutathione (D) Reduced to oxidized glutathione ratio. n = 4, mean ± SEM, 
two-way ANOVA with Tukey’s post-hoc test. * represents genotypic difference while # 
represents difference between diet.  
 
 
 
 
C D
A B
C
D
H
F D
0
2 0
4 0
6 0
8 0
L iv e r  C a rb o n y l C o n te n t
(n
m
o
l/m
g
 p
ro
te
in
)
W T
G R X 2 + /-#  #
*
C D H F
D
0
5
1 0
1 5
M u s c le  C a rb o n y l C o n te n t
(n
m
o
l/m
g
 p
ro
te
in
)
W T
G R X 2 + /-
C
D
H
F D
0
2 0 0
4 0 0
6 0 0
8 0 0
1 0 0 0
T
o
ta
l G
lu
ta
th
io
n
e
(n
m
o
l/m
L
) W T
G R X 2 + /-
C
D
H
F D
0
2
4
6
8
S
e
ru
m
 G
S
H
/G
S
S
G
 r
a
tio
W T
G R X 2 + /-
#
Interaction P=0.0244
Diet P=0.0055
Genotype P=0.1198
Interaction P=0.6615
Diet P=0.0277
Genotype P=0.1979
 85 
3.4 Evaluation of Grx2+/- Mitochondrial Respiration When Challenged with a HFD 
3.4.1 Liver Mitochondria 
  As noted above, no differences in mitochondrial ROS production by liver mitochondria 
oxidizing pyruvate, succinate, or palmitoyl-carnitine were observed. This prompted us to 
examine the impact of diet and genotype on mitochondrial bioenergetics. Evaluation of 
mitochondrial bioenergetics was conducted using a Clark-electrode, allowing validation of 
mitochondrial function and health (93). The different respiratory steady-states are defined based 
on the typical addition of substrates. State 1 respiration refers to O2 consumption by 
mitochondria alone and is minimal since there is a lack of fuel. State 2 respiration is O2 
consumption after addition of a substrate (pyruvate/malate or succinate in this case) and reflects 
the basal rate of proton conductance back into the matrix. Addition of ADP primes state 3 
respiration, allowing formation of ATP by complex V, coupled to proton return into the matrix. 
Oxygen consumption therefore reflects regeneration of the proton gradient during this state. State 
4 respiration reflects O2 consumption under non-phosphorylating conditions, once all ADP has 
been converted to ATP. Oligomycin is added during this state controlling for possible 
contaminating ATP synthases that could work in reverse, allowing an accurate measure of proton 
leak-dependent respiration. The use of pyruvate allows measurement of the rate of O2 
consumption from electrons donated to complex I, while succinate supplementation results in 
rates from donation of electrons to complex II. Note that rotenone is added to succinate-driven 
respiration to prevent reverse electron transfer to complex I, allowing an accurate measure of O2 
consumption from complex II-linked substrates.   
 Rates of oxygen consumption by liver mitochondria revealed no significant effect of diet 
or genotype on the states of respiration (Figure 3.10A-B). Indeed, no significant differences in 
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phosphorylating and non-phosphorylating respiration were observed with liver mitochondria 
energized with either pyruvate or succinate. There was a large amount of error in my 
measurements, which I attributed to succinate serving as a poor substrate for respiration. Next, I 
calculated the respiratory control ratio (RCR), a proxy measure for the efficiency of ATP 
production, using the state 3 and state 4 respiration rate data. Results for RCR in liver 
mitochondria followed the same trend as rates of O2 consumption with no significant genotypic 
or diet effect observed (Figure 3.10C-D). Additionally, the high RCR when pyruvate served as 
the substrate indicates that the mitochondrial population being studied is well-coupled and thus 
healthy. However, succinate was not a good driver for respiration or ATP production, as 
indicated by the variable RCR and low state 3 respiration. When compared to pyruvate 
metabolism, state 3 respiration during succinate oxidation is ~85% lower. These findings are 
consistent with a previous study published by our group (88). 
3.4.2 Muscle Mitochondria 
Muscle tissue undergoes repeated cycles of contraction and relaxation powering the 
energetically expensive process of locomotion. Therefore, muscle mitochondria are required to 
produce an abundance of ATP. This can be observed when you evaluate the state 3 respiration 
between liver and muscle mitochondria (Figure 3.11-3.12). The consumption of oxygen is 
clearly higher in muscle mitochondria (~20 to 25 nmol min-1 mg-1) compared to liver 
mitochondria (~12 nmol min-1 mg-1), when evaluating pyruvate metabolism. Additionally, there 
was a significant increase in Grx2+/- mice challenged with a CD when metabolizing succinate 
(Figure 3.11B). No other significant differences in rate of O2 were found when mitochondria 
were supplemented with malate/pyruvate or succinate (Figure 3.11A-B). Furthermore, no 
significant difference in RCR for muscle mitochondria was observed (Figure 3.11C-D). It is 
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important to note that in male mice, it was determined that muscle mitochondria had 
significantly increased state 3 and state 4 respiration during malate/pyruvate- and succinate-
driven respiration for Grx2 +/- mice (59). It was determined that this increased respiration led to 
the DIO protective effect displayed in those mice and further experimentation uncovered that the 
increase in state 4 respiration was due to enhanced proton leak through UCP3 (59). These results 
were not reproducible in female Grx2 +/- mice.  
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Figure 3.10: Rates of oxygen consumption by liver mitochondria supplemented with (A) 
Pyruvate (10 mM)/malate (2 mM) (B) Succinate (2 mM)/rotenone (4 µM) (C-D) Respiratory 
control ratios, represented as state 3/state 4. Mitochondria were diluted to 0.5 mg/mL in the 
reaction chamber and state 2 respiration initiated by addition of substrate, state 3 
(phosphorylating respiration) initiated by addition of ADP (1 mM), state 4 (leak-dependent 
respiration) initiated by addition of oligomycin (4 µg/mL), and baseline of oxygen consumption 
was determined by addition of antimycin A (4 µM); for which all O2 consumption values were 
corrected. n = 4-6, mean ± SEM, two-way ANOVA. 
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Figure 3.11: Rates of oxygen consumption by muscle mitochondria supplemented with (A) 
Pyruvate (10 mM)/malate (2 mM) (B) Succinate (2 mM)/rotenone (4 µM) (C-D) Respiratory 
control ratios, represented as state 3/state 4. Mitochondria were diluted to 0.2 mg/mL and state 2 
respiration initiated by addition of substrate, state 3 (phosphorylating respiration) initiated by 
addition of ADP (1 mM), state 4 (leak-dependent respiration) initiated by addition of oligomycin 
(4 µg/mL), and baseline of oxygen consumption was determined by addition of antimycin A (4 
µM); for which all O2 consumption values were corrected. Pyruvate n = 3-5, Succinate n = 2-4 (n 
= 2 for WT/CD); mean ± SEM, two-way ANOVA with Tukey’s post-hoc test. * represents 
difference within state from WT (CD). 
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Chapter 4: Discussion 
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4.1 Summary  
The first discovery of a metabolic difference in GRX2 deficient mice was observed in a study 
by Mailloux et al. in 2013 (60). In that study, it was found that total body and lower gonadal 
white adipose tissue mass was significantly lower in male GRX2-/- mice (60). These phenotypic 
changes in mass due to the deletion of the Grx2 gene correlated strongly with an increase in 
overall energy metabolism and proton leaks in muscle (60). Recently, our group evaluated if the 
Grx2+/- phenotype could protect male mice from DIO and the development of related disorders. 
It was found that male WT mice subjected to a HFD gained weight rapidly, which was 
associated with hypertrophy of white fat, higher circulating levels of triglycerides, intrahepatic 
lipid accumulation, and depletion of liver glycogen stores (59). However, male mice 
heterozygous for the Grx2 gene fed a HFD displayed a weight gain profile similar to the control 
group (59). This was associated with increased muscle fuel metabolism, proton leaks, and 
protection from oxidative stress in muscle (59).  
Measurement of body and adipose mass, food and water consumption, and serum triglyceride 
levels revealed that female WT mice were resistant to DIO. These results are in contrast to male 
WT mice, which showed significant increases in total body and adipose mass, and circulating 
triglycerides and insulin (59). Furthermore, measurement of organ masses found that livers from 
female mice fed a HFD had lower mass compared to their CD counterparts, an observation even 
more apparent in Grx2+/- mice. Previous work in the lab utilizing male mice showed no alteration 
in liver mass of Grx2+/- or Grx2-/- mice compared to WT littermates (18).  
Measurement of the rate of O2•-/H2O2 production by liver and muscle mitochondria revealed 
an augmentation of O2•-/H2O2 production in Grx2+/-/HFD mice when liver mitochondria were 
supplemented with pyruvate/malate. It has been documented that PDH is a high-capacity site for 
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O2•-/H2O production in liver mitochondria (52,92). It has been shown that O2•-/H2O2 production 
by PDH and KGDH is modulated by GRX2 and S-glutathionylation reactions (41,52). Therefore, 
it is not surprising that there is augmented ROS in the Grx2+/- mice challenged with a HFD. 
However, it was surprising to only observe this in liver, as muscle mitochondria were resistant to 
any augmentation but found to be augmented by Grx2 deletion in males (59).  
Evaluation of the oxidative state of liver mitochondria with a protein carbonyl assay revealed 
that there was significantly less protein oxidation in Grx2+/- mice and mice challenged with a 
HFD. There also was a decrease in the GSH: GSSG ratio when mice were challenged with a 
HFD, indicating a higher level of oxidized glutathione during high-fat feeding. These findings 
suggest an increase in oxidative stress resulting in upregulation of antioxidant pathways when 
mice are challenged with a HFD or deficiency in Grx2. Work by Yang et al. support these 
findings as they demonstrated a significant increase of liver O2•-/H2O2 production in male ob/ob 
C57BL/6 mice that had developed obesity and fatty liver (94). Subsequently this group was able 
to show a significant upregulation of enzymatic activity of SOD2 and catalase in these obese 
mice (94). 
Results from mitochondrial respiration experiments suggest no alteration in mitochondrial 
respiration between WT and Grx2+/- mice when oxidizing complex I or II substrates. However, 
there was a small increase in respiration of Grx2+/- mice on a CD when supplemented with ADP 
and succinate. Whereas in the male study, there was a ~2-fold increase in state 3 and state 4 
respiration for both pyruvate and succinate driven respiration (59).  
4.2 Female Obesity 
The chromosomal make-up that determines biological sex in a fetus occurs during embryonic 
development and due to the paternal inheritance of either an X or Y chromosome. The default 
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sex of a developing fetus is female (XX), which can be switched to male differentiation 
following the expression of the sex-determining region Y (SPY) gene on the Y-chromosome 
(95). This gene encodes a transcription factor for testis development that alters hormone 
secretion and the fate of the embryo towards male (XY) development (95). In the present study, 
there is an inherent protection against obesity in female mice on a HFD. This is not unexpected 
as health issues such as cardiovascular disease, interstitial cystitis, and stroke show distinct sex 
differences in symptoms and onset (95,96). For example a conservative estimate for the 
prevalence of interstitial cystitis is 8:2 for female to male, a 4-fold sex difference (96). 
Additionally, there is an increase incidence of abdominal fat accumulation, hyperlipidemia, 
insulin resistance, and cardiovascular disease in post-menopausal women, correlating to a drastic 
decrease in estrogen secretion (95).  
The estrogen-related receptor family of transcription factors have been found to regulate 
metabolic genes, as both the nucleus and mitochondrial membranes have estrogen receptors (81). 
Indeed 17-b estradiol has a direct link to promotion of genes regulating lipid metabolism and 
mitochondria function (76,80). Estrogen additionally has been shown to influence the browning 
of adipose tissue, the process of turning white adipose tissue into brown adipose tissue. This is 
achieved through increases the metabolic activity of these tissues by increasing mitochondrial 
abundance and upregulation of UCP1 (97). Estrogen through estrogen receptor-a can regulate 
brain-derived neurotrophic factor, which is linked to inducing browning (97). Estrogen increases 
atrial natriuretic peptide and brain natriuretic peptide which has been linked to white adipose 
tissue browning (97). The eating patterns in female mice have similarly been shown to be cyclic 
with ovarian cycles with food consumption at its peak during estrus, when estradiol is lowest 
(97).  
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Obesity is classified as an inflammatory disease and with 80% of autoimmune diseases 
occurring in women, inflammation seems to be strongly sex-linked (95). Female mice have a lot 
of physiological similarities to humans and reach sexual maturity at 6 to 8 weeks, making them a 
good experimental model to evaluate sex differences in research (98). Indeed, in mice there are 
differences between sexes observed in inflammatory markers when fed a HFD (95). One 
difference being that male adipocytes are infiltrated by M1 macrophages and they express higher 
levels of inflammatory cytokines, while female adipocytes are infiltrated by M2 macrophages 
(95). There is also a sexual dimorphism with fat disposition, as males are more likely to 
accumulate visceral fat, while females have a tendency to accumulate subcutaneous fat (95). This 
sex difference in fat deposits is due to differential rates of fatty acid uptake by adipocytes in 
these regions (95). 
Likewise, there is a sex difference observed in the onset of obesity in mice, as male mice 
show increased weight gain during juvenile age (~ six weeks), while females are more 
predisposed to weight gain later in their life cycle (~31 weeks of age) (99). This correlates well 
with observations in this study, as female mice did not show overall body or adipose tissue mass 
gain from 3 to 10 weeks of age on a HFD. Additionally, these mice did not show elevated 
triglyceride levels while on a HFD. This finding is supported by literature demonstrating pre-
menopausal women typically have higher HDL and lower LDL levels, allowing for better free 
fatty acid clearance than males (95). Altogether, this may highlight a limitation to the current 
study, as the sample of mice used was 3 to 10 weeks of age. There may have been more 
pronounced differences found if female mice from later stages in life (~31 weeks) were utilized, 
as they would have been more predisposed to developing DIO.    
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4.3 Importance of Female Based Studies 
4.3.1 Differences to Male Study 
This study highlights the importance of including female animals in study designs and the 
inability to generalize male studies to female populations. Indeed, there are distinct sex 
differences between the preceding male study and this study in female littermates under similar 
experimental parameters. The most noticeable difference is the resistance in female mice to 
overall body and adipose mass gain when fed a HFD. However, this has been reported before in 
LDL receptor null mice, where a HFD induced both body and adipose mass increases in the male 
mice but failed to do so in females (30). Females, however still developed hypercholesterolemia 
in that study, due to their inability to uptake cholesterol via LDL receptors (30). Furthermore, sex 
differences in mice body mass gain when on a HFD was abolished by performing ovariectomies, 
indicating a hormonal influence (97).  
A few studies have focused on whether or not sex differences affect cell redox signalling 
pathways. In regard to the role of S-glutathionylation in regulating mitochondrial functions, 
studies have mostly focused on rodent models (18,41,59,88). Recently, our group found that 
male mice carrying a deletion for Grx2 are protected from DIO and the development of related 
disorders (59). This was associated with increased muscle fuel combustion and ROS generation, 
the latter of which plays an important role in muscle physiology (59). The increase in fuel 
combustion was associated with increased proton leaks through UCP3 and ANT, resulting in 
increased muscle O2 consumption (59). Differences in S-glutathionylation profiles have been 
discovered between female and male mice, but very few studies have narrowed in on sex 
differences in S-glutathionylation and its impact on redox signalling (30). For example in a large 
scale proteomic study of macrophages, 47 proteins in female mice vs 17 in male were 
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exclusively S-glutathionylated when challenged with a HFD for 10 weeks (30). Also in this 
study, they assessed the cellular pathways most affected by S-glutathionylation. The pathways 
most affected in females were for cell differentiation and inflammatory response, while for males 
the top pathways were H2O2 metabolism and response to stress (30). The 2-fold increase in 
response to cellular stress in females along with there not being a need to upregulate antioxidant 
or stress response pathways, indicate female mice are better equipped to deal with metabolic 
stress. 
In terms of oxidative stress, when comparing the measurements of protein carbonyls in 
muscle mitochondria between both the male and female studies I see a stark difference. In the 
previous male study, the protein carbonyl content in Grx2+/- mice was the same as the control, 
regardless of whether they were placed on a HFD (59). The WT mice on HFD, however, showed 
a greater then 2-fold increase in protein carbonyls (59). The protection from oxidative stress in 
male Grx2+/- mice was accompanied by higher serum total glutathione levels along with a more 
reduced glutathione pool (59). In males, this demonstrated an adaptive response of the Grx2+/- 
mice to deal with oxidative stress by enhancing antioxidant capacity. In female mice there is no 
alteration of the protein carbonyl content in muscle of either group. Additionally, there was no 
change in the level of total glutathione, but there was instead a higher content of oxidized 
glutathione for the Grx2+/- mice on a HFD. This possibly demonstrates a more efficient capacity 
for female muscle mitochondria to deal with oxidative stress without having to compensate with 
upregulating antioxidants. On the other hand, this could be due to the fact that female 
mitochondria produce less ROS than their male counterparts. Indeed, this has been shown for 
female mouse brain mitochondria as they have lower levels of H2O2 and decreased oxidative 
stress than male brains (81). Additionally, as stated above, one of the key pathways S-
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glutathionylated, in response to stress, in macrophages of male mice was H2O2 metabolism (30). 
Evidently, the processes for H2O2 metabolism were found to have a significant decrease in S-
glutathionylation in female macrophages (30).  
In female liver mitochondria, there are contradictory protein carbonyl findings as there 
was a significant decrease in protein carbonyl content for WT mice on a HFD and Grx2+/- mice 
on either diet. Unfortunately, the previous male study did not isolate liver mitochondria and 
therefore, a comparison could not be made; however, a similar comparison was conducted by 
another group. A key study by Yamamoto et al. compared the antioxidant capacity in livers of 
female and male rats, under sedentary or active conditions (100). They determined that in the 
active mice (oxidative stress-inducing conditions), GSH levels were elevated in female rats 
compared to males (100). Additionally, they found that the activities of GPX, GR, and g-
glutamyltranspeptidase (an enzyme initiating the membrane-crossing transport of GSH) were 2-
fold higher in female rat livers under both sedentary and active conditions (100). Also relevant to 
our study is the fact that GPX activity of female rats increased from the sedentary to active 
groups, while there was no adaptive response in the male rats (100). These findings support the 
possibility of an antioxidant adaptation to the HFD in female mice, but a lack of  adaptation in 
males. 
4.3.2 Altered Female ROS production  
The results presented herein support other findings by our group that demonstrate that sex 
has an impact on ROS production by liver and muscle mitochondria (88). Indeed, a recent study 
in our lab supports no genotypic alteration in liver O2•-/H2O2 production when oxidizing 
pyruvate, a-ketoglutarate, and succinate in mice with a partial or full deletion of Grx2 (88). 
Additionally, this previous study did not show any genotypic difference in O2•-/H2O2 production 
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for skeletal muscle mitochondria (88). In male mice, however, a significant increase in O2•-/H2O2 
generation in liver and cardiac muscle was found with deletion of Grx2 (18). Production of O2•-
/H2O2 in liver mitochondria with a deletion or deficiency of Grx2 resulted in decreased O2•-
/H2O2 release when oxidizing pyruvate and a-ketoglutarate, but the reverse was observed when 
oxidizing succinate (18). Alternatively, in cardiac mitochondria deletion or deficiency of Grx2 
augmented O2•-/H2O2 production with these 3 substrates (18). A similar trend was observed in 
male skeletal muscle mitochondria as Grx2 deficiency results in augmented O2•-/H2O2 production 
when oxidizing pyruvate, succinate, and palmitoyl-carnitine (59). The current study, while 
observing a small genotypic difference for liver mitochondria supplemented with pyruvate, 
observed no significant difference between WT and Grx2+/- mice for muscle or liver, which is in 
line with what was previously observed (88).   
Furthermore, when comparing rates of O2•-/H2O2 production between sexes, female mice 
produced significantly less O2•-/H2O2 when supplemented with pyruvate and a-ketoglutarate but 
more when supplemented with succinate in liver mitochondria, compare to males (88). However, 
when oxidizing these substrates in muscle mitochondria females produced significantly more 
O2•-/H2O2, with a ~6-fold increase for pyruvate (88). Comparing rates of O2•-/H2O2 production 
from this study with those previously observed in males, WT/CD mice have a 2-fold increase 
when supplemented with pyruvate or succinate, but about the same production when oxidizing 
palmitoyl-carnitine, consistent with current literature (59). With PDH, KGDH, and complex II 
ROS-generating abilities regulated by S-glutathionylation, these results suggest sexual dimorphic 
regulation of ROS production by S-glutathionylation.  
This sex difference in ROS production has been a focus of study by the Neufer group 
(77,78). Studies by this lab have been able to highlight that 17b-estradiol localizes to the MIM 
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and influences microviscosity of the MIM and ETC function (78). Taken further, they were able 
to determine that knockdown of 17b-estradiol causes increased H2O2 production by complex I in 
skeletal muscle (77). Interestingly, this effect was not observed in liver mitochondria, but instead 
treatment of 17b-estradiol decreased state 3 respiration (78). This supports other findings in liver 
mitochondria that show a reduced state 3 respiration in females compared to males (88). This 
further explains why a decline in 17b-estradiol, such as during menopause in women, correlates 
to an increased risk of obesity, insulin resistance, and cardiovascular disease (77). It may be 17b-
estradiol that is responsible for the metabolic sexual dimorphisms observed for differential ROS 
generation and better mitochondrial coupling observed in females (80). 
4.3.3 Role of GRX2  
The deletion of Grx2 has serious effects such as heart disease, hypertension, cataract 
formation, and hindering embryonic development (4). It is for these reasons that in the following 
study, heterozygous mice for the Grx2 gene were utilized to avoid any extraneous variables 
influencing the study outcomes. Comparisons of the Grx2+/- mouse model between sexes show a 
2-fold increase in liver O2•-/H2O2 production in male mice compared to female mice 
supplemented with succinate (18). When comparing pyruvate oxidation between male and 
female Grx2 deficient mice, again a 2-fold increase in production was observed in males. This 
augmented O2•-/H2O2 production in males was also seen in muscle mitochondria (59). It has been 
observed that in male skeletal muscle mitochondria that S-glutathionylation reactions regulate 
complex I through the NDUFS1 subunit and regulate pyruvate influx by inhibiting MPC (41). 
Also, GRX2 has been shown to form part of the redox interface by modulating O2•-/H2O2 
production, as complex II requires GRX2 to reduce ROS when oxidizing succinate (18).  
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However the results from this study indicate that GRX2 is not required from female mice 
to maintain either O2•-/H2O or mitochondrial bioenergetics and ATP production. This indicated a 
possible difference in the role of GRX2 for female mice. However, to my knowledge, this is the 
first time the role of GRX2 has been investigated in females and therefore requires more work to 
be done to elucidate the role of GRX2 in females. This sex-specific role of GRX2 does not come 
as a surprise since it has been shown that GRX2 has a tissue-specific effect (18).   
4.3.4 Altered Fuel Combustion  
In a previous study comparisons among WT, Grx2+/-, and Grx2-/- female mice liver and 
muscle mitochondria were made. It was found that liver mitochondria has significant increases in 
state 3 respiration for Grx2+/- and Grx2-/- mice when oxidizing pyruvate and increased state 4 
respiration when oxidizing succinate (88). These results were not reproduced in this thesis as 
there was no significant difference in liver mitochondrial bioenergetics observed. It should be 
emphasized, that in the study cited above, mice were not subjected to dietary manipulation (88). 
Indeed, it has been documented that mitochondria from mice fed different diets can display 
alterations in bioenergetics (30,59). In terms of skeletal muscle mitochondria, there was no 
changes in state 3 respiration when fuelled by complex I or II substrates, which is also confirmed 
in this thesis (88). However, there was a significant increase in state 3 respiration in female 
Grx2+/- mice on a CD when supplemented with succinate and ADP. Additionally in our previous 
study a significant decrease in proton leak-dependent respiration was observed in Grx2 deficient 
mice when supplemented with succinate (88). This observation was absent here as there was no 
change in proton leak in liver or muscle mitochondria for pyruvate or succinate fuel metabolism.  
When overall fuel combustion is compared between male and female studies, results show 
lower fuel oxidation in female mitochondria in all groups oxidizing succinate and pyruvate (59). 
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These findings might be considered to be surprising since the Broushel group has shown that 
human female skeletal muscle requires a smaller population of mitochondria to achieve the same 
respiratory output as males (84). This disparity is linked to female mitochondria having a higher 
intrinsic respiration capacity and increased O2 affinity (84). This group postulated that this could 
be due to a higher cristae density, which has been observed to occur in endurance athletes, or a 
higher abundance of supercomplexes and respirasomes (84). My results, do not support their 
findings as when I matched mitochondrial content for male and female studies, we did not see a 
higher respiration rate in female mice muscle or liver mitochondria. The Broushel group also 
found a 2-fold higher intrinsic proton leak in human female skeletal muscle mitochondria, a 
finding also not supported by our results (84). As mitochondrial ROS production and 
bioenergetics have been found to be both animal- and strain-dependent, and because our study 
was conducted in mice, these differences could be explained by differences in models. Also, the 
Broushel study looked a specific section of the vastus lateralis muscle while our preparations 
utilized total muscle from pectoral, hindlimb, and forelimb (84). The type of muscle fibre does 
influence the bioenergetics of the mitochondria isolated from it.  
In this study, we observed a distinct reduction in the capacity of female mitochondria to 
utilize succinate as a substrate. When comparing WT male and female mice, succinate oxidation 
was 10-fold higher in state 3 respiration in males. Similar results were found in a previous study 
in our lab where direct comparison showed a 3x increase in succinate driven state 3 respiration in 
male liver mitochondria compared to female (88). These are not surprising findings since it has 
been documented that complex II in vastus lateralis muscle is less active in females (101). It has 
also been documented that glycolytic enzyme activities for females are significantly lower than 
for males (101). Moreover, a more recent study found higher levels of succinic acid in urine 
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samples of females, indicating a failure to metabolize this metabolite (96). This is not surprising 
as women have a greater abundance of type I muscle fibres and a preference for oxidation of 
fatty acids (84,102). This difference in muscle fibres underlines another limitation of this study 
as the type of muscle fibre from which the mitochondria were isolated was not controlled in my 
study, nor was mitochondrial respiration performed with a fatty acid source such as palmitoyl-
carnitine.  
4.4 Conclusions 
To conclude, this study showed that female WT mice were completely resistant to DIO, 
unlike their male WT littermates. Additionally while the ROS generation and redox environment 
in liver mitochondria seem to be altered between WT and Grx2+/- mice, this trend does not hold 
true for muscle mitochondria. Lastly, bioenergetics data suggest no genotypic difference between 
these mice when fueled by complex I or II substrates. These results collectively indicate an 
alteration in the role for GRX2 in female mice. Therefore, this study suggests that a sexual 
dimorphism exists for mitochondrial redox signalling through the GRX2 pathway. 
4.5 Future Directions  
Future work to build off previous research in the lab and this study will further investigate 
the role of GRX2 in mice and the sexual dimorphisms present. This will include: 
1. Completing fatty acid fuel mitochondrial respiration in female GRX2 deficient mice 
challenged with a HFD. 
2. Further investigation of the GRX2 deficient mouse model with muscle specific 
knockouts of Grx2. 
3. Investigate sexual dimorphisms of S-glutathionylation between male and female mice 
and how these differences alter O2•-/H2O2 production and redox signalling.  
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